Payload Delivery System

Submicron particles with lipid structures and pH-responsive amphiphilic polymer chains address the challenges of RNA delivery by enhancing stability and enabling room temperature storage, facilitating efficient cytoplasmic delivery and targeted delivery of nucleic acids.

JP2024544515APending Publication Date: 2024-12-03IMPERIAL COLLEGE INNVOATIONS LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024527332
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-10
Filing Date
2022-11-10
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The clinical translation and commercialization of RNA systems, such as mRNA and saRNA, are limited by inefficient in vivo delivery, high natural immunogenicity, instability, and the need for ultra-cold storage due to their large molecular weight and fragile nature.

Method used

Development of submicron particles comprising a lipid structure and amphiphilic polymer chains that respond to external stimuli, allowing for controlled and targeted delivery of nucleic acids, including saRNA and small molecule payloads, with enhanced stability for long-term storage at room and tropical temperatures.

Benefits of technology

The submicron particles provide efficient cytoplasmic delivery of nucleic acids, stabilize macromolecular payloads, and eliminate the need for ultra-cold storage, enabling stable formulations that can be stored at room temperature.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544515000019
    Figure 2024544515000019
  • Figure 2024544515000020
    Figure 2024544515000020
  • Figure 2024544515000021
    Figure 2024544515000021
Patent Text Reader

Abstract

The present disclosure provides a submicron particle comprising a first payload molecule, a lipid structure, and a plurality of amphiphilic polymer chains surrounding the lipid structure. The first payload molecule is a macromolecule, optionally a nucleic acid. Furthermore, the hydrophobicity of the amphiphilic polymer chain changes in response to an external stimulus.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to payload delivery systems such as submicron particles, in particular the submicron particles themselves which comprise a payload molecule such as a macromolecule, e.g. a nucleic acid. The invention extends to methods of producing the submicron particles, pharmaceutical compositions and vaccines comprising the submicron particles, and to medical uses thereof. [Background technology]

[0002] Research into vaccines and biopharmaceuticals based on nucleic acids, especially messenger RNA (mRNA) and self-amplifying RNA (saRNA), has become increasingly popular over the past decade. mRNA-based vaccines and biopharmaceuticals represent a promising alternative to traditional approaches due to their high potency, capacity for rapid development, potential for low-cost manufacturing, large-scale deployment, and safe administration. The mRNA vaccine and biopharmaceutical field is developing extremely rapidly. The approval of the Pfizer / BioNTech and Moderna mRNA COVID vaccines marks the first time that in vitro transcribed mRNA has been approved for human use, making mRNA a key asset in major pharmaceutical and biotechnology pipelines. This emerging platform has tremendous innovation potential for use not only as a vaccine platform against various infectious diseases, but also as a biopharmaceutical against cancer, genetic, and other diseases. saRNA is another popular option thanks to its ability to produce 10-100 times more antigen from an extremely small dose compared to mRNA, due to increased intracellular replication of the antigen-encoding saRNA. 1 Many studies in animal models have shown that foreign antigens expressed by saRNA viral vectors generate strong immune responses and provide long-term protection in immunized animals against tumor cells and infectious agents. 2 .

[0003] However, the clinical translation and commercialization of RNA systems is limited by their inefficient in vivo delivery, high natural immunogenicity and instability. RNA systems, especially mRNA and saRNA, have poor endocytosis due to their large molecular weight and high negative charge. In addition, limited intracellular protein expression is a challenge due to their endosomal trapping and catalytic hydrolysis. Moreover, RNA is very fragile and can easily degrade in exposed environments, thus requiring storage and distribution in very challenging ultra-cold or cold chains.

[0004] To address these challenges, new delivery systems are urgently needed. Despite great technological advances, targeted intracellular delivery of nucleic acids, including RNA, remains a challenge. Although viral vectors are known to have high transfection efficiency, the clinical use of such delivery systems is limited due to safety concerns, challenges in large-scale production and the need for more rapid development. Therefore, non-viral vectors, such as cationic lipid nanoparticles (LNPs), are promising alternatives. Nevertheless, conventional nanoparticles have poor stability, high immunogenicity and unfavorable biodistribution, limiting their clinical applications. Summary of the Invention

[0005] The present invention represents an effort by the inventors to overcome problems associated with the prior art.

[0006] According to a first aspect of the present invention, there is provided a submicron particle comprising a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains surrounding the lipid structure, wherein the first payload molecule is a macromolecule, optionally a nucleic acid, and the hydrophilicity of the amphiphilic polymer chains changes in response to an external stimulus.

[0007] The inventors have found that the submicron particles of the first aspect can address the problems associated with the prior art by using functional polymers and targeting ligands to provide more controlled and targeted delivery. As discussed in the examples, the submicron particles developed by the inventors have demonstrated effective cytoplasmic delivery of functional macromolecular payloads such as saRNA as well as co-delivery of saRNA and small molecule payloads such as ruxolitinib. The inventors have also found that the submicron particles can stabilize macromolecular payloads such as nucleic acids, allowing for long-term stable storage of both lyophilized and aqueous formulations at room and tropical temperatures. This therefore eliminates the need for ultra-low temperature or cryogenic storage.

[0008] The term "submicron" may be understood to mean that the particles of the invention have a maximum maximum dimension of less than 1 μm. More preferably, the maximum dimension of the particles is less than 900 nm, less than 800 nm, less than 700 nm or less than 600 nm, most preferably less than 500 nm, less than 400 nm, less than 300 nm or less than 200 nm. Submicron particles may have a maximum maximum dimension between 10-900 nm, between 20-800 nm, between 30-700 nm or between 40-600 nm, more preferably between 50-500 nm or between 60-400 nm, most preferably between 80-300 nm or between 100-200 nm. The maximum maximum dimension of the submicron particles may correspond to the Z-average size determined using a Zetasizer μV instrument.

[0009] The first payload molecule is preferably encapsulated in the lipid structure.Alternatively or additionally, the first payload molecule may be covalently conjugated and / or physically attached to the outer surface of the lipid structure.The physical attachment described elsewhere herein may be by electrostatic interaction and / or hydrophobic interaction.

[0010] Suitable macromolecules that may be used as the first payload molecule preferably have a molecular weight of at least 900 Daltons, at least 1000 Daltons or at least 1200 Daltons.

[0011] The macromolecule may be a nucleic acid, a peptide, an affimer, a protein, an antibody or fragment thereof, a glycoprotein, a lipopolysaccharide, or a carbohydrate. The macromolecule may be a lipid or a macrocycle.

[0012] However, preferably, the first payload molecule is a nucleic acid. The nucleic acid may be a DNA, RNA or a DNA / RNA hybrid sequence. Preferably, the nucleic acid is DNA or RNA.

[0013] Most preferably, the nucleic acid is RNA.RNA can be single-stranded or double-stranded.RNA can be selected from the group consisting of messenger RNA (mRNA); self-amplifying RNA (saRNA); antisense RNA (asRNA); RNA aptamer; interfering RNA (RNAi); microRNA (miRNA); short interfering RNA (siRNA); short hairpin RNA (shRNA); and small RNA.

[0014] Preferably, the RNA is a self-amplifying RNA (saRNA). Preferably, the RNA is a messenger RNA (mRNA). Those skilled in the art will recognize that the self-amplifying RNA may contain the basic elements of mRNA (cap, 5'UTR, 3'UTR, and variable length poly(A) tail), but may be quite long (e.g., 9-12 kb).

[0015] The nucleic acid sequence, preferably RNA, can be at least 10 bases in length, at least 20 bases in length, at least 50 bases in length, at least 100 bases in length, at least 200 bases in length, at least 300 bases in length, at least 400 bases in length, at least 500 bases in length, at least 600 bases in length, at least 700 bases in length, at least 800 bases in length or at least 900 bases in length.

[0016] In a preferred embodiment, the RNA is saRNA or mRNA.

[0017] The nucleic acid sequence, preferably RNA, most preferably saRNA or mRNA, can be at least 1000 bases in length, at least 2000 bases in length, at least 3000 bases in length, at least 4000 bases in length, at least 5000 bases in length, at least 6000 bases in length, at least 7000 bases in length, at least 8000 bases in length, at least 9000 bases in length, at least 10000 bases in length, at least 11000 bases in length or at least 12000 bases in length.

[0018] In one embodiment, the nucleic acid sequence is at least 6000 bases in length. In one embodiment, the RNA is at least 6000 bases in length. In a preferred embodiment, the saRNA is at least 6000 bases in length.

[0019] In an alternative embodiment, the nucleic acid sequence is at least 900 bases in length. In one embodiment, the RNA is at least 900 bases in length. In a preferred embodiment, the mRNA is at least 900 bases in length.

[0020] The nucleic acid sequence, preferably RNA, most preferably saRNA, can be between 5,000 and 20,000 bases in length, between 5,500 and 15,000 bases in length, between 6,000 and 14,000 bases in length, between 6,500 and 13,000 bases in length, between 7,000 and 12,000 bases in length, between 8,000 and 11,000 bases in length, or between 9,000 and 10,000 bases in length.

[0021] Alternatively, the nucleic acid sequence, preferably RNA, most preferably mRNA, can be between 50 and 10,000 bases in length, between 100 and 9,000 bases in length, between 200 and 8,000 bases in length, between 300 and 7,000 bases in length, between 400 and 6,000 bases in length, between 500 and 6,000 bases in length, between 600 and 5,000 bases in length, between 700 and 4,000 bases in length, between 800 and 3,000 bases in length, or between 900 and 2,000 bases in length.

[0022] In one embodiment, the nucleic acid sequence is between 6,000 and 15,000 bases in length. The nucleic acid sequence may be between 8,000 and 12,000 bases in length. The RNA may be between 6,000 and 15,000 bases in length. The RNA may be between 8,000 and 12,000 bases in length. Preferably, the saRNA is between 6,000 and 15,000 bases in length. Preferably, the saRNA is between 8,000 and 12,000 bases in length.

[0023] In alternative embodiments, the nucleic acid sequence is between 400 and 14000 bases long, between 500 and 10000 bases long, between 600 and 7500 bases long, between 700 and 5000 bases long, between 800 and 4000 bases long, or between 900 and 2000 bases long. The RNA can be between 400 and 14000 bases long, between 500 and 10000 bases long, between 600 and 7500 bases long, between 700 and 5000 bases long, between 800 and 4000 bases long, or between 900 and 2000 bases long. Preferably, the mRNA is between 400 and 14000 bases long, between 500 and 10000 bases long, between 600 and 7500 bases long, between 700 and 5000 bases long, between 800 and 4000 bases long, or between 900 and 2000 bases long.

[0024] One of skill in the art will recognize that when the nucleic acid is double-stranded, e.g., double-stranded RNA or DNA, "base length" refers to the length of base pairs.

[0025] The lipid structure may be a lipid nanoparticle or a liposome. Preferably, the or each lipid structure is a lipid nanoparticle.

[0026] In some embodiments, the lipid structure may comprise multiple lipids.

[0027] At least one of the plurality of lipids may comprise a cationic or ionizable lipid. The cationic or ionizable lipid may be a multivalent cationic lipid. The cationic or ionizable lipid may be a pH-sensitive lipid. The cationic or ionizable lipid may comprise a positively charged or ionizable nitrogen atom. The cationic or ionizable lipid may exhibit a positive charge in an acidic solution. A solution may be understood to be acidic if it has a pH of less than 7 at 20°C, more preferably less than 6.5 at 20°C. A solution may be understood to be acidic if it has a pH of between 3.5 and 7 at 20°C, or between 4 and 7 at 20°C, more preferably between 4.5 and 6.5 at 20°C.

[0028] The cationic or ionizable lipid can be dioleoyl-3-trimethylammonium propane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), ethylphosphatidylcholine (ethyl PC), didodecyldimethylammonium bromide (DDAB), 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-cholesterol), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), DLin-MC3-DMA, 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), or heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102). In some embodiments, the cationic or ionizable lipid is dioleoyl-3-trimethylammonium propane (DOTAP). In some embodiments, the cationic or ionizable lipid is DLin-MC3-DMA. In some embodiments, the cationic or ionizable lipid is DODAP.

[0029] The cationic or ionizable lipids may comprise at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, or at least 55% by weight of the plurality of lipids. The cationic or ionizable lipids may comprise between 5-80% or between 10-60% by weight of the plurality of lipids. In some embodiments, the cationic or ionizable lipids may comprise between 20-50% or between 25-35% by weight of the plurality of lipids. In alternative embodiments, the cationic or ionizable lipids may comprise between 30-70%, between 40-65%, or between 50-60% by weight of the plurality of lipids.

[0030] The lipid structure and / or the lipids may comprise one or more helper lipids.In one embodiment, the helper lipid may be zwitterionic, for example, phosphatidylcholine (including DOPC, DSPC, DPPC, DDPC, DLPC, DMPC, POPC, DEPC, L-α-phosphatidylcholine) or phosphatidylethanolamine (including DOPE, DMPE, DPPE, DSPE).

[0031] Alternatively, in another embodiment, the helper lipid can be non-zwitterionic, such as phosphatidylglycerol (including DOPG, DMPG, DPPG, DSPG, POPG), phosphatidylserine (including DOPS) and phosphatidic acid (including DMPA, DPPA, DSPA). Thus, in some embodiments, at least one of the lipids may not include a zwitterionic lipid. Thus, in other words, the submicron particles of the present invention may not contain or may not include a zwitterionic lipid. However, in other embodiments, at least one of the lipids may include a zwitterionic lipid. A zwitterionic lipid may contain an equal number of positively charged functional groups and negatively charged functional groups and exhibit a net charge of zero at a zwitterionic pH. The zwitterionic pH may vary depending on the zwitterionic lipid. In some embodiments, the zwitterionic pH may be understood to be an acidic pH. Thus, a zwitterionic pH may be understood to be a pH between 1 and 8 at 20°C, between 2 and 7 at 20°C, between 3 and 6 at 20°C, between 4 and 5 at 20°C, or between 4.3 and 4.5 at 20°C.

[0032] The zwitterionic lipid may contain a positively charged nitrogen atom. The zwitterionic lipid may contain a negatively charged oxygen atom. The oxygen atom may be bound to a P(O) group or a C(O) group. The zwitterionic lipid may be a phosphatidylcholine (including DOPC, DSPC, DPPC, DDPC, DLPC, DMPC, POPC, DEPC, L-α-phosphatidylcholine) or a phosphatidylethanolamine (including DOPE, DMPE, DPPE, DSPE). The zwitterionic lipid may be 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or L-α-phosphatidylcholine (PC). In some embodiments, the zwitterionic lipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). Non-zwitterionic lipids can be phosphatidylglycerols (including DOPG, DMPG, DPPG, DSPG, POPG), phosphatidylserines (including DOPS) and phosphatidic acids (including DMPA, DPPA, DSPA).

[0033] The weight ratio of cationic or ionizable lipid to helper lipid may be between 20:1 and 1:20, between 10:1 and 1:10, or between 5:1 and 1:5. In some embodiments, the weight ratio of cationic or ionizable lipid to helper lipid may be between 4:1 and 1:4, between 3:1 and 1:3, between 2:1 and 1:2, between 1.5:1 and 1:1.5, or between 1.8:1 and 1:1.8. In alternative embodiments, the weight ratio of cationic or ionizable lipid to helper lipid may be between 1:1 and 1:10, between 1:2 and 1:8, or between 1:4 and 1:5. In some embodiments. The weight ratio of cationic or ionizable lipid to helper lipid is about 1:1.

[0034] The helper lipid may comprise at least 5%, at least 10%, at least 20% or at least 30% by weight of the plurality of lipids. In some embodiments, the helper lipid may comprise at least 40% or at least 50% by weight of the plurality of lipids. The helper lipid may comprise between 5-80% or between 10-70% by weight of the plurality of lipids. In some embodiments, the helper lipid may comprise between 20-50% or between 25-35% by weight of the plurality of lipids. In alternative embodiments, the helper lipid may comprise between 30-60% or between 50-60% by weight of the plurality of lipids. In further alternative embodiments, the helper lipid may comprise between 2-40%, between 4-30%, between 6-25%, between 8-20% or between 10-15% by weight of the plurality of lipids.

[0035] At least one of the plurality of lipids may comprise a sterol. The sterol may be C 1~24 It may be or may comprise an alkyl phytosterol, stigmasterol or stigmastanol. Preferably, the sterol is cholesterol.

[0036] Sterols may comprise at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, or at least 40% by weight of the plurality of lipids. Sterols may comprise between 1-80%, between 2-70%, or between 5-60% by weight of the plurality of lipids. In some embodiments, sterols may comprise between 10-55%, between 20-50%, between 30-45%, or between 35-45% by weight of the plurality of lipids. In alternative embodiments, sterols may comprise between 2-40%, between 4-30%, between 5-20%, between 6-15%, or between 7-10% by weight of the plurality of lipids. In alternative embodiments, sterols may comprise between 10-50%, between 20-40%, or between 25-30% by weight of the plurality of lipids.

[0037] At least one of the plurality of lipids may comprise a PEGylated lipid. A PEGylated lipid may be understood to be a lipid modified to include a polyethylene glycol (PEG) group or a derivative thereof. A derivative of PEG may be understood to be a multi-arm PEG, a functionalized PEG, and the like. In some embodiments, the shield lipid may be a DMG, DSPE, or DPPC lipid modified to include a PEG group or a derivative thereof. Thus, the PEGylated lipid may be a DMG-PEG, PEG-DSPE, or PEG-DPPC. The PEG group may have an average molecular weight between 100 and 20,000 Da, between 200 and 15,000 Da, between 300 and 10,000 Da, between 400 and 7,500 Da, or between 500 and 5,000 Da. In some embodiments, the PEG group may have an average molecular weight between 1,000 and 3,000 Da, between 1,250 and 1,750 Da, between 1,500 and 2,500 Da, between 1,750 and 2,250 Da, or between 1,900 and 2,100 Da. In some embodiments, the PEG group may have an average molecular weight between 2,000 and 8,000 Da, between 3,000 and 7,000 Da, between 4,000 and 6,000 Da, between 4,500 and 5,500 Da, or between 4,750 and 5,250 Da. The average molecular weight may be a number average molecular weight or a weight average molecular weight.

[0038] The PEGylated lipid may comprise at least 0.1%, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4% or at least 5% by weight of the lipids. The PEGylated lipid may comprise between 0.1-50%, between 0.5-40%, between 1-30%, between 2-20%, between 3-10%, between 4-8% or between 5-7% by weight of the lipids.

[0039] Submicron particles may have an N / P ratio of at least 1:100, at least 1:50, at least 1:10 or at least 1:5, more preferably at least 1:3, at least 1:2 or at least 1:1, most preferably at least 2:1, at least 3:1, at least 4:1, at least 5:1, at least 6:1, at least 7:1, at least 8:1 or at least 9:1. Submicron particles may have an N / P ratio of less than 100:1, less than 50:1, less than 40:1, less than 30:1, less than 28:1, less than 26:1, less than 24:1, less than 22:1, less than 21:1 or less than 20:1. Submicron particles may have an N / P ratio between 1:100 and 100:1, between 1:50 and 80:1, between 1:10 and 60:1, between 1:5 and 50:1, between 1:3 and 40:1, between 1:2 and 30:1, between 1:1 and 25:1, between 2:1 and 20:1, between 5:1 and 15:1, or between 8:1 and 12:1. In a preferred embodiment, the submicron particles have an N / P ratio between 9:1 and 11:1. The N / P ratio may be understood as the ratio between the cationic amines in the lipid structure and the anionic phosphates in the payload molecules.

[0040] The ratio of the first payload molecule (preferably a nucleic acid, more preferably an RNA) to lipid is 2.5×10 -9 The ratio may be between 0.1 and 0.25:1.

[0041] The external stimulus may be a pH change, a temperature change, and / or exposure to light. Thus, the hydrophilicity of the amphiphilic polymer chain may decrease in response to a decrease in pH. Thus, the hydrophilicity of the amphiphilic polymer chain may decrease in response to an increase in temperature or exposure to light.

[0042] Preferably, the polymer chain permeabilizes the lipid membrane in response to an external stimulus. The external stimulus can be a chemical stimulus, which can be selected from pH change, a specific redox potential, a specific ion or a specific gas. Alternatively, the stimulus can be a physical stimulus, which can be selected from temperature change, light or electromagnetic field change. Alternatively, the stimulus can be a biochemical stimulus, which can be selected from protein, peptide, enzyme, glucose or nucleic acid, such as DNA.

[0043] In some embodiments, the external stimulus is a pH change.

[0044] Advantageously, pH-responsive polymers can mimic anionic peptides, particularly on the surface of viruses that play a role in membrane destabilization, to allow endosomal escape of the payload into the cytoplasm. As discussed in the Examples, the inventors have shown that pH-responsive polymers can have endosomolytic activity and can facilitate cytoplasmic delivery of the payload when used as part of the submicron particles of the invention.

[0045] The multiple amphiphilic polymer chains may be prepared as described in WO 2018 / 011580, WO 2021 / 260392 and / or Chen et al. 4 The amphiphilic polymer may be or may include a polymer as described in. The amphiphilic polymer may be responsive to an external stimulus. The external stimulus may be pH.

[0046] WO 2021 / 260392 relates to a new polymerization method and the use of this method to synthesize new polymers, including polyesters, polyethers, and polyester-ethers. It has been reported that these types of polymers can be temperature responsive. Other temperature responsive polymers can include or include poly(N-isopropylacrylamide-co-methacrylic acid).

[0047] Furthermore, the polymer may be conjugated to certain other components through a linker that responds to stimuli such as light, heat, enzymes, etc., if appropriate or necessary. One example is that a membrane-permeabilizing polymer can be made membrane inactive by conjugation through a "shield" component. Upon reaching the target site, the linker can be cleaved with a specific stimulus, and the polymer is converted to a membrane-permeabilizing state. Alternatively, these polymers may be conjugated to one or more components that respond to stimuli such as pH, light, heat, enzymes, etc.

[0048] The amphiphilic polymer chains may be negatively charged at a pH of at least 4 at 20° C., at least 5 at 20° C., at least 6 at 20° C., at least 6.5 at 20° C. or at least 7 at 20° C. The amphiphilic polymer chains may be negatively charged at a pH between 4 and 10 at 20° C., between 5 and 9 at 20° C., between 6 and 8 at 20° C. or between 6.5 and 7.5 at 20° C.

[0049] The amphiphilic polymer chain may contain at least one COOH group. The COOH group may be deprotonated at a pH above its pKa, i.e., COO - and thus it can be appreciated that the amphiphilic polymer is relatively hydrophilic. However, at a pH below its pKa, the COO - The groups can be protonated, i.e., COOH, and therefore the amphiphilic polymer is more hydrophobic. Thus, the hydrophilicity of the groups decreases at low pH.

[0050] The amphiphilic polymer chain comprises one or more mers of formula I: -L1 -CH(L 3 -COR 1 )-L 2 - [I] (In the formula, L 1 is optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, optionally substituted C 3~20 Cycloalkylene, optionally substituted C 3~20 Cycloalkenylene, optionally substituted C 3~20 Cycloalkynylene, optionally substituted C 3~12 Heterocyclylene, optionally substituted C 6~20 Arylene, optionally substituted C 5~10 Heteroarylene, CO, O, S and NR 4 comprising one or more linker elements selected from the group consisting of: L 2 and L 3 C is independently absent or optionally substituted. 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, optionally substituted C 3~20 Cycloalkylene, optionally substituted C 3~20 Cycloalkenylene, optionally substituted C 3~20 Cycloalkynylene, optionally substituted C 3~12 Heterocyclylene, optionally substituted C 6~20 Arylene, optionally substituted C 5~10 Heteroarylene, CO, O, S and NR 4 comprising one or more linker elements selected from the group consisting of: Each R 1 is independent, NR 6 R 7 , OR 10 or OH; R 4 is H, optionally substituted C 1~30Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 is alkynyl; R 6 and R 7 each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 is alkynyl; R 10 is optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 alkynyl) may include.

[0051] In some embodiments, the amphiphilic polymer chain may include two or more mers of formula I, which may be the same or different from each other.

[0052] Preferably, in at least one of the mers of formula I, R 1 is OH.

[0053] In some embodiments, the amphiphilic polymer chain comprises one or more mers of formula II: -L 4 - [II] (In the formula, L 4 is optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, optionally substituted C 3~20 Cycloalkylene, optionally substituted C 3~20 Cycloalkenylene, optionally substituted C 3~20 Cycloalkynylene, optionally substituted C 3~12 Heterocyclylene, optionally substituted C 6~20 Arylene, optionally substituted C 5~10 Heteroarylene, CO, O, S and NR4 comprising one or more linker elements selected from the group consisting of: R 4 is as defined above) may include.

[0054] In some embodiments, the amphiphilic polymer chain may include two or more mers of formula II, which may be the same or different from each other.

[0055] The amphiphilic polymer chain may have a random sequence. Alternatively, the amphiphilic polymer chain may have a controlled sequence. For example, the amphiphilic polymer chain may be a block copolymer.

[0056] In some embodiments, the amphiphilic polymer chain comprises a plurality of polymers of formula III:

[0057] [ka]

[0058] (In the formula, L 1 ~L 4 , R 1 , R 4 , R 6 and R 7 is as defined above; X 1 is absent or O, S or NR 5 and; R 2 is H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl, optionally substituted C 2~30 Alkynyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20cycloalkynyl, an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 3- to 20-membered heterocycle; R 3 and R 5 each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 is alkynyl; n is an integer and is at least 1; m is an integer that is 0 or at least 1. is or contains

[0059] One or more -L 4 -blocks, which may be the same or different from one another, may be present.

[0060] One or more -L 1 -CH(L 3 -COR 1 )-L 2 -blocks, which may be the same or different from one another, may be present.

[0061] The polymers can have random or controlled sequences.

[0062] The term "alkyl," as used herein, unless otherwise specified, refers to a saturated straight-chain or branched hydrocarbon. An alkyl can be a primary, secondary, or tertiary hydrocarbon. 1~30 Alkyl includes, for example, methyl, ethyl, n-propyl (1-propyl), isopronyl (2-propyl, 1-methylethyl), butyl, pentyl, hexyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl. The or each alkyl may be optionally substituted C 1~30 Alkyl, optionally substituted C 1~20 Alkyl, optionally substituted C 1~12 Alkyl, optionally substituted C1~6 Alkyl or optionally substituted C 1~3 The alkyl group may be an alkyl group. The alkyl group may be unsubstituted or substituted. Substituted alkyl groups include halogen, CN, NO2, COOR 8 , N.R. 8 R 9 , OR 8 , S.R. 8 , SSR 8 ,CONR 8 R 9 , N3, OP(O)OR 8 R 9 , P.R. 8 R 9 , oxo, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 R is optionally substituted with one or more substituents selected from the group consisting of cycloalkynyl, optionally substituted 5- to 20-membered heteroaryl, and optionally substituted 3- to 20-membered heterocycle; 8 and R 9 each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl, optionally substituted C 2~30 Alkynyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 It is cycloalkynyl, an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 3- to 20-membered heterocycle.

[0063] The term "alkylene," as used herein, unless otherwise specified, refers to a divalent saturated straight or branched chain hydrocarbon. Optionally substituted alkylenes are similar to the optionally substituted alkyls defined above, except that a hydrogen atom has been removed therefrom making the alkyl group divalent.

[0064] The term "alkenyl" refers to an olefinically unsaturated hydrocarbon group that may be unbranched or branched. Thus, an alkenyl may contain one or more double bonds between adjacent carbon atoms. 2~ C 30 Alkenyl includes, for example, vinyl, allyl, propenyl, butenyl, pentenyl and hexenyl. The or each alkenyl may be optionally substituted C 2~20 Alkenyl, optionally substituted C 2~12 Alkenyl, optionally substituted C 2~6 Alkenyl or optionally substituted C 2~3 The alkenyl group may be unsubstituted or may be substituted with halogen, CN, NO2, COOR 8 , N.R. 8 R 9 , OR 8 , S.R. 8 , SSR 8 ,CONR 8 R 9 , N3, OP(O)OR 8 R 9 , P.R. 8 R 9 , oxo, optionally substituted C 2~30 Alkynyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 R is optionally substituted with one or more substituents selected from the group consisting of cycloalkynyl, optionally substituted 5- to 20-membered heteroaryl, and optionally substituted 3- to 20-membered heterocycle; 8 and R 9 each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl, optionally substituted C 2~30 Alkynyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C3~20 Cycloalkenyl, optionally substituted C 3~20 It is cycloalkynyl, an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 3- to 20-membered heterocycle.

[0065] The term "alkenylene," as used herein, unless otherwise specified, refers to a divalent, olefinically unsaturated, straight or branched chain hydrocarbon. Optionally substituted alkenylene is similar to the optionally substituted alkenyl defined above, except that a hydrogen atom has been removed therefrom making the alkyl group divalent.

[0066] The term "alkynyl" refers to an acetylenically unsaturated hydrocarbon group that may be unbranched or branched. Thus, an alkynyl may contain one or more triple bonds between adjacent carbon atoms. An alkynyl group may further contain one or more double bonds between adjacent carbon atoms. C2-C 30 Alkynyl includes, for example, propargyl, propynyl, butynyl, pentynyl and hexynyl. The or each alkynyl may be optionally substituted C 2~30 Alkynyl, optionally substituted C 2~20 Alkynyl, optionally substituted C 2~12 Alkynyl, optionally substituted C 2~6 Alkynyl or optionally substituted C 2~3 The alkynyl group may be unsubstituted or substituted with halogen, CN, NO2, COOR 8 , N.R. 8 R 9 , OR 8 , S.R. 8 , SSR 8 ,CONR 8 R 9 , N3, OP(O)OR 8 R 9 , P.R. 8 R 9 , oxo, optionally substituted C 2~30 Alkenyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 R is optionally substituted with one or more substituents selected from the group consisting of cycloalkynyl, optionally substituted 5- to 20-membered heteroaryl, and optionally substituted 3- to 20-membered heterocycle; 8 and R 9 each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl, optionally substituted C 2~30 Alkynyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 It is cycloalkynyl, an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 3- to 20-membered heterocycle.

[0067] The term "alkynylene," as used herein, unless otherwise specified, refers to a divalent acetylenically unsaturated straight or branched hydrocarbon. Optionally substituted alkynylene is similar to the optionally substituted alkynyl defined above, except that a hydrogen atom has been removed therefrom making the alkyl group divalent.

[0068] "Aryl" refers to an aromatic 6- to 20-membered hydrocarbon group. 20 Examples of aryl groups include, but are not limited to, phenyl, α-naphthyl, β-naphthyl, biphenyl, tetrahydronaphthyl and indanyl. The or each aryl may be optionally substituted C 6~12 It may be aryl.

[0069] "Cycloalkyl" refers to a non-aromatic, saturated, monocyclic, bicyclic or polycyclic hydrocarbon 3- to 20-membered ring system. The or each cycloalkyl may be optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~12Cycloalkyl or optionally substituted C 3~6 Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0070] "Cycloalkenyl" refers to a non-aromatic, olefinically unsaturated, monocyclic, bicyclic or polycyclic hydrocarbon 3- to 20-membered ring system. Thus, a cycloalkenyl may contain one or more double bonds between adjacent carbon atoms in the ring. The or each cycloalkenyl may be an optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~12 Cycloalkenyl or optionally substituted C 3~6 It may be a cycloalkenyl.

[0071] "Cycloalkynyl" refers to a non-aromatic, acetylenically unsaturated, monocyclic, bicyclic or polycyclic hydrocarbon 3- to 20-membered ring system. Thus, a cycloalkynyl may contain one or more triple bonds between adjacent carbon atoms in the ring. A cycloalkenyl may also contain one or more double bonds between adjacent carbon atoms in the ring. The or each cycloalkynyl may be an optionally substituted C 3~20 Cycloalkynyl, optionally substituted C 3~12 Cycloalkynyl or optionally substituted C 3~6 It may be a cycloalkynyl.

[0072] "Heteroaryl" refers to a monocyclic or bicyclic aromatic 5- to 20-membered ring system in which at least one ring atom is a heteroatom. The or each heteroatom may be independently selected from the group consisting of oxygen, sulfur, nitrogen, and phosphorus. The heteroaryl may be an optionally substituted 5- to 20-membered heteroaryl or an optionally substituted 5- to 10-membered heteroaryl. Examples of 5-20 membered heteroaryl groups include furan, thiophene, indole, azaindole, oxazole, thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole, 1-methyl-1,2,4-triazole, 1H-tetrazole, 1-methyltetrazole, benzoxazole, benzothiazole, benzofuran, benzisoxazole, benzimidazole, N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline, quinoline, and isoquinoline. Bicyclic heteroaryl groups include, for example, those in which a phenyl, pyridine, pyrimidine, pyrazine, or pyridazine ring is fused to a 5- or 6-membered monocyclic heteroaryl ring.

[0073] "Heterocycle" or "heterocyclyl" refers to a 3- to 20-membered monocyclic, bicyclic, polycyclic or bridged molecule in which at least one ring atom is a heteroatom. The or each heteroatom may be independently selected from the group consisting of oxygen, sulfur, nitrogen and phosphorus. The heterocycle may be saturated or partially saturated. The heterocyclic group may be an optionally substituted 3- to 20-membered heterocycle or an optionally substituted 3- to 12-membered heterocycle. Exemplary 3- to 20-membered heterocyclic groups include, but are not limited to, aziridine, oxirane, oxirene, thiirane, pyrroline, pyrrolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, dithiolane, piperidine, 1,2,3,6-tetrahydropyridin-1-yl, tetrahydropyran, pyran, morpholine, piperazine, thiane, thiine, piperazine, azepane, diazepane, and oxazine.

[0074] The aryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl or heterocyclyl groups may be unsubstituted or may be substituted with halogen, CN, NO2, COOR. 8 , N.R. 8 R 9 , OR 8 , S.R. 8 , SSR 8 ,CONR 8 R 9 , N3, OP(O)OR 8 R 9 , P.R. 8 R 9 , oxo, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl, optionally substituted C 6~20 Aryl, optionally substituted C 2~30 Alkynyl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 R is optionally substituted with one or more substituents selected from the group consisting of cycloalkynyl, optionally substituted 5- to 20-membered heteroaryl, and optionally substituted 3- to 20-membered heterocycle; 8 and R 9 each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl, optionally substituted C 2~30 Alkynyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 It is cycloalkynyl, an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 3- to 20-membered heterocycle.

[0075] Similarly, the arylene, cycloalkylene, cycloalkenylene, cycloalkynylene, heteroarylene, and heterocyclylene groups are analogous to the aryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, and heterocyclyl groups defined above, except that they are divalent.

[0076] In some embodiments, m is 0.

[0077] In some embodiments, L 3 is non-existent.

[0078] R 2 and R 3 are independently H or optionally substituted C 1~12 More preferably, R 2 and R 3 is H or C 1~6 alkyl, and even more preferably R 2 and R 3 is H or C 1~3 It is an alkyl.

[0079] X 1 may be non-existent.

[0080] Thus, in some embodiments, the amphiphilic polymer chain comprises a plurality of polymers of formula IV:

[0081] [ka]

[0082] is or contains

[0083] In some embodiments, L 1 has the following structure: -CO-L 5 -CO-NR 4 -L 6 - (In the formula, L 5is optionally substituted C 6~12 Arylene or optionally substituted C 5~10 is a heterocyclylene; L 6 is optionally substituted C 1~12 Alkylene, optionally substituted C 2~12 Alkenylene or optionally substituted C 2~12 alkynylene) has.

[0084] L 5 can be optionally substituted phenylene, and is preferably unsubstituted phenylene.

[0085] L 6 is optionally substituted C 1~12 Alkylene, preferably optionally substituted C 2~6 It may be alkylene, more preferably -(CH2)4-.

[0086] R 4 is preferably H.

[0087] L 2 is NR 4 It can be. R 4 is preferably H.

[0088] Thus, in some embodiments, the polymer of formula IV has formula IVa:

[0089] [ka]

[0090] has.

[0091] The amphiphilic polymer chains may have a number average molecular weight of at least 1 kDa, at least 2 kDa, at least 5 kDa, at least 10 kDa, at least 15 kDa, at least 20 kDa, at least 22 kDa, at least 24 kDa, at least 24.5 kDa or at least 24.8 kDa. The amphiphilic polymer chains may have a number average molecular weight of less than 250 kDa, less than 100 kDa, less than 75 kDa, less than 50 kDa, less than 40 kDa, less than 30 kDa, less than 28 kDa, less than 26 kDa, less than 25.5 kDa or less than 25 kDa. The amphiphilic polymer chains may have a number average molecular weight between 1 and 250 kDa, between 2 and 100 kDa, between 5 and 75 kDa, between 10 and 50 kDa or between 15 and 40 kDa, more preferably between 20 and 30 kDa, between 22 and 28 kDa, between 24 and 26 kDa or between 24.5 and 25.5 kDa, most preferably between 24.8 and 25 kDa.

[0092] n can be an integer of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8. n can be an integer less than 50, less than 40, less than 30, less than 25, less than 20, less than 15, less than 12, or less than 10. n can be an integer between 1 and 50, between 2 and 40, between 3 and 30, between 4 and 25, between 5 and 20, between 6 and 15, between 7 and 12, or between 8 and 10.

[0093] Alternatively, n can be an integer of at least 5, at least 10, at least 15, at least 25, at least 50, at least 75, at least 90, or at least 95. n can be an integer less than 5,000, less than 1,000, less than 500, less than 250, less than 150, less than 125, less than 110, or less than 105. n can be an integer between 5 and 5,000, between 10 and 1,000, between 15 and 500, between 25 and 250, between 50 and 150, between 75 and 125, between 90 and 110, or between 95 and 105. Typically, n can be an integer between 10 and 1,000, between 15 and 750, between 25 and 500, between 40 and 250, between 60 and 200, between 90 and 170, between 110 and 150, or between 120 and 140.

[0094] In further alternative embodiments, n can be an integer of at least 100, at least 250, at least 500, at least 750, at least 1,000, at least 1,250, or at least 1,500.

[0095] In some embodiments, m can be an integer that is at least 1. Thus, m can be an integer that is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, or at least 45. m can be an integer less than 1,000, less than 500, less than 250, less than 150, less than 100, less than 80, less than 70, less than 60, or less than 55. m can be an integer between 5 and 1,000, between 10 and 500, between 15 and 250, between 20 and 150, between 25 and 100, between 30 and 80, between 35 and 70, between 40 and 60, or between 45 and 55.

[0096] In embodiments where m is an integer of at least 1, the ratio of n to m can be between 1:25 and 50:1, between 1:10 and 30:1, between 1:5 and 15:1, between 1:2 and 10:1, between 1:1 and 5:1, or between 1.5:1 and 3:1. In some embodiments, the ratio of n to m is 2:1.

[0097] It can be appreciated that by controlling the ratio of n to m, the hydrophilicity of the amphiphilic polymer can be controlled.

[0098] L 1 is optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene or optionally substituted C 2~30 More preferably, L 1 is optionally substituted C 1~6 Alkylene, optionally substituted C 2~6 Alkenylene or optionally substituted C 2~6 alkynylene, most preferably L 1 is C1~3 Alkylene, C 2~3 Alkenylene or C 2~3 Alkynylene. Therefore, L 1 can be -CH2-.

[0099] L 2 are CO, O, S and NR 4 In some embodiments, L may include one or more linker elements selected from the group consisting of 2 CO and NR 4 In an alternative embodiment, L may include or be one or two linker elements selected from 2 may include or be one or more linker elements selected from the group consisting of CO, O and S, more preferably L 2 may contain one or two linker elements, CO and O. Thus, L 2 can be O, CO or COO.

[0100] L 3 is optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, CO, O, S and NR 4 The linker element may include one or more linker elements selected from the group consisting of:

[0101] In some embodiments, L 3 -L 7 -L 8 -L 9 - may be L 7 and L 9 C is independently absent or optionally substituted; 1~30 Alkylene, optionally substituted C 2~30 Alkenylene or optionally substituted C 2~30 Alkynylene; L 8 may independently be absent or may be CO, O, S, and NR 4and L may include one or more linker elements selected from the group consisting of 7 ~L 8 At least one of is present.

[0102] L 7 and L 9 are independently optionally substituted C 1~15 Alkylene, optionally substituted C 2~15 Alkenylene or optionally substituted C 2~15 More preferably, L 7 and L 9 are independently optionally substituted C 1~6 Alkylene, optionally substituted C 2~6 Alkenylene or optionally substituted C 2~6 alkynylene, most preferably L 7 and L 9 is independent, C 1~3 Alkylene, C 2~3 Alkenylene or C 2~3 Alkynylene. Therefore, L 7 and L 9 may each be -CH2CH2-.

[0103] L 8 can be CO, COO, O or S, is preferably O or S, and is more preferably S.

[0104] L 4 is optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, CO, O, S and NR 4 The linker element may include one or more linker elements selected from the group consisting of:

[0105] In some embodiments, L 4 -L 10 -L 11 - may be L 10 is optionally substituted C 1~30Alkylene, optionally substituted C 2~30 Alkenylene or optionally substituted C 2~30 Alkynylene; L 11 can be absent or can be CO, O, S and NR 4 The linker element may comprise one or more linker elements selected from the group consisting of:

[0106] L 10 is optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene or optionally substituted C 2~30 More preferably, L 10 is optionally substituted C 10~15 Alkylene, optionally substituted C 10~15 Alkenylene or optionally substituted C 10~15 alkynylene, most preferably L 10 is branch C 10~15 Alkylene, Branched C 10~15 Alkenylene or branched C 10~15 Alkynylene. Therefore, L 10 can be -CHCH((CH)CH)-.

[0107] L 11 can be O or S, preferably O.

[0108] R 2 is H or optionally substituted C 1~12 More preferably, R 2 is H or optionally substituted C 1~6 alkyl, and even more preferably R 2 is optionally substituted C 1~3 It is an alkyl group. Therefore, R 2 may be optionally substituted methyl, optionally substituted ethyl or optionally substituted propyl. Alkyl is C 6~20The alkyl may be substituted with phenyl. Thus, in some embodiments, R 2 is -CH2-C6H5.

[0109] R 3 is H or optionally substituted C 1~12 More preferably, R 3 is H or optionally substituted C 1~6 alkyl, and even more preferably R 3 is H or optionally substituted C 1~3 It is an alkyl.

[0110] X 1 is O, S or NR 5 It could be. X 1 is preferably O.

[0111] Thus, in some embodiments, the polymer can be a polymer L, as described in WO 2021 / 260392. 100 F 50 It can be. 100 F 50 The structure of is provided below.

[0112] [ka]

[0113] It will be appreciated that alternative multifunctional, membrane-permeabilizing multiblock polymers falling within the scope of Formula I may also be prepared using the methods described in WO 2021 / 260392.

[0114] In some embodiments, R in the polymer 1 At least 1% of the groups are OH, more preferably at least 1% of the R 1 At least 5%, at least 10% or at least 15% of the groups are OH, more preferably at least 5%, at least 10% or at least 15% of the groups in the polymer are OH. 1At least 20%, at least 22%, or at least 24% of the groups are OH. In some embodiments, the R 1 At least 25%, at least 30%, or at least 35% of the groups are OH. In some embodiments, the R 1 At least 50%, at least 60%, at least 70% or at least 80% of the groups are OH. In some embodiments, R 1 Less than 99%, less than 95% or less than 90% of the groups are OH, more preferably less than 99%, less than 95% or less than 90% of the R 1 Less than 85% of the groups are OH. In some embodiments, the R 1 Less than 75%, less than 60%, less than 50%, or less than 45% of the groups are OH. In some embodiments, R 1 Less than 40%, less than 35%, less than 30%, less than 28%, or less than 26% of the groups are OH. 1 Between 1 and 99% of the groups are OH, and more preferably, the R 1 Between 5 and 85% of the groups are OH. In some embodiments, the R 1 Between 10-60%, between 15-40%, between 20-35%, between 22-30%, or between 24-26% of the groups are OH. 1 Between 10-80%, between 15-70%, between 20-60%, between 30-50%, or between 35-45% of the groups are OH. 1 Between 50 and 92%, or between 60 and 90%, or between 70 and 88%, or between 75 and 86%, or between 80 and 84% of the groups are OH.

[0115] In some embodiments, R in the polymer 1 At least 1%, at least 5% or at least 10% of the groups are NR 6 R 7 OR 10 and more preferably, R 1 At least 15% of the groups are NR 6 R 7 OR 10In some embodiments, R in the polymer 1 At least 25%, at least 50% or at least 60% of the groups are NR 6 R 7 OR 10 In some embodiments, R in the polymer 1 At least 65%, at least 70%, at least 72% or at least 74% of the groups are NR 6 R 7 OR 10 In some embodiments, R in the polymer 1 Less than 99% of the groups are NR 6 R 7 OR 10 and more preferably, R 1 Less than 95%, less than 90%, or less than 85% of the groups are NR 6 R 7 OR 10 and more preferably, R 1 Less than 80%, 78%, or 76% of the groups are NR 6 R 7 OR 10 In some embodiments, R in the polymer 1 Less than 70% or less than 65% of the groups are NR 6 R 7 OR 10 In some embodiments, R in the polymer 1 Less than 60%, less than 40%, less than 30%, less than 25%, or less than 20% of the groups are NR 6 R 7 OR 10 In some embodiments, R in the polymer 1 Between 1 and 99%, between 5 and 98%, or between 10 and 97% of the groups are NR 6 R 7 OR 10 and more preferably, R 1 Between 15 and 95% of the groups are NR 6 R 7 OR 10 In some embodiments, R in the polymer 1Between 40-90%, 60-85%, 65-80%, 70-78%, or 74-76% of the groups are NR 6 R 7 OR 10 In some embodiments, R in the polymer 1 Between 20-80%, 30-75%, 40-70%, 50-67.5%, 55-65%, or 57.5-62.5% of the group is NR 6 R 7 OR 10 In some embodiments, R in the polymer 1 Between 2.5-60%, between 5-50%, between 7.5-40%, between 10-30%, between 12.5-25%, or between 15-20% of the group is NR 6 R 7 OR 10 It is.

[0116] In an alternative embodiment, R in the polymer 1 At least 30% of the groups are OH and the R 1 At least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the groups are OH. In some embodiments, the R 1 100% of the groups may be OH. This embodiment is preferred when m is an integer of at least 1.

[0117] OH R 1 It can be appreciated that by controlling the percentage of groups, the hydrophilicity of the polymer can be controlled.

[0118] In some embodiments, the polymer is a polymer of formula IVa, where R 1 100% of the groups are OH.

[0119] R 6 and R 7 are independently H, optionally substituted C 1~20 Alkyl, optionally substituted C 2~20 Alkenyl or optionally substituted C 2~20More preferably, R 6 and R 7 are independently H, optionally substituted C 1~12 Alkyl, optionally substituted C 2~12 Alkenyl or optionally substituted C 2~12 It may be alkynyl.

[0120] R 6 can be H.

[0121] In one embodiment, R 7 is optionally substituted C 1~6 Alkyl, optionally substituted C 2~6 Alkenyl or optionally substituted C 2~6 The alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more of the substituents defined above. In some embodiments, the alkyl, alkenyl or alkynyl is unsubstituted or substituted with halogen, COOH, oxo, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 The alkyl, alkenyl or alkynyl is substituted with one or more of halogen, COOH, oxo, C 6~20 Aryl, C 3~20 Cycloalkyl, C 3~20 Cycloalkenyl, C 3~20 cycloalkynyl, 5-20 membered heteroaryl, or 3-20 membered heterocycle. In some embodiments, the alkyl is substituted with COOH and optionally further substituted with phenyl or 1H-indolyl.

[0122] Therefore, R 7 teeth

[0123] [ka]

[0124] More preferably, R 7 teeth

[0125] [ka]

[0126] In some embodiments, R 7 teeth

[0127] [ka]

[0128] and more preferably

[0129] [ka]

[0130] Thus, the polymer may include phenylalanine side chains.

[0131] In some embodiments, the polymer comprises at least one R 1 The group is NR 6 R 7 and R 6 is H and R 7 but

[0132] [ka]

[0133] is a polymer of formula IVa,

[0134] More preferably, R 7 teeth

[0135] [ka]

[0136] In the most preferred embodiment, R 7 teeth

[0137] [ka]

[0138] It is.

[0139] In an alternative embodiment, R 7 is optionally substituted C 3~25 Alkyl, optionally substituted C 3~25 Alkenyl or optionally substituted C 3~25 More preferably, R 7 is optionally substituted C 5~20 Alkyl, optionally substituted C 5~20 Alkenyl or optionally substituted C 5~20 Alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more of the substituents defined above. In some embodiments, alkyl, alkenyl or alkynyl is unsubstituted or substituted with halogen, COOH, oxo, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 In some embodiments, R is substituted with one or more of an optionally substituted cycloalkynyl, an optionally substituted 5-20 membered heteroaryl, or an optionally substituted 3-20 membered heterocycle. 7 is C 5~20 In an alternative embodiment, R 7 is C 5~20 It is a substituted alkyl. The alkyl may be substituted with COOH.

[0140] Therefore, R 7 are -(CH2)6CH3, -(CH2)9CH3, and -(CH2) 13 CH3, -(CH2) 17 CH3 or -(CH2) 11 It can be COOH.

[0141] In some embodiments, the polymer comprises at least one R 1 The group is NR 6 R 7 and R 6 is H and R 7 -(CH2)6CH3, -(CH2)9CH3, -(CH2) 13 CH3, -(CH2) 17 CH3 or -(CH2) 11 COOH.

[0142] These polymers are anionic amphiphilic polycarboxylates containing hydrophobic pendant chains and ionizable carboxylic acid groups. They are designed to mimic the structure and pH-responsive membrane permeabilization activity of the anionic fusogenic peptide in the hemagglutinin spike of influenza virus. These biomimetic polymers are simple to synthesize and exhibit pH-responsive membrane activity due to their ability to change conformation from coiled to globular when the pH is lowered below their pKa.

[0143] The polymer chains may be conjugated to the lipid structure or may not be conjugated to the lipid structure. In a preferred embodiment, the polymer chains are not conjugated to the lipid structure. The polymer chains may interact with the lipid structure by electrostatic and / or hydrophobic forces.

[0144] Submicron particles may contain at least 100 or at least 500 polymer chains, more preferably at least 1,000, at least 2,000, at least 4,000, at least 6,000, at least 8,000 or at least 10,000 polymer chains. Submicron particles may contain between 50 and 1,000,000 polymer chains, or between 100 and 100,000 or between 500 and 50,000 polymer chains, more preferably between 1,000 and 40,000, between 2,000 and 30,000, between 4,000 and 25,000, between 6,000 and 20,000, between 8,000 and 15,000 or between 10,000 and 13,000 polymer chains.

[0145] The submicron particles may contain polymer chains at a concentration of at least 0.01 mg / ml, at least 0.05 mg / ml, at least 0.1 mg / ml, at least 0.2 mg / ml, at least 0.25 mg / ml, at least 0.3 mg / ml, at least 0.5 mg / ml, at least 0.75 mg / ml or at least 1 mg / ml. The submicron particles may contain polymer chains at a concentration between 0.01 and 25 mg / ml, between 0.05 and 10 mg / ml, between 0.1 and 5 mg / ml, between 0.2 and 2.5 mg / ml, between 0.25 and 2 mg / ml, between 0.3 and 1.5 mg / ml or between 0.5 and 1 mg / ml.

[0146] In some embodiments, the exterior surface of the lipid structure is completely saturated with multiple polymer chains.

[0147] It can be recognized that submicron particle can comprise one or more lipid structures.More preferably, submicron particle can comprise a single lipid structure.Therefore, the number of polymer chains shown above can be regarded as the number of polymer chains per lipid structure, preferably the number of polymer chains per lipid nanoparticle.

[0148] The submicron particles may be negatively charged at a pH of at least 5 at 20° C., at least 6 at 20° C., at least 6.5 at 20° C. or at least 7 at 20° C. The submicron particles may be negatively charged at a pH between 5 and 9 at 20° C., between 6 and 8 at 20° C. or between 6.5 and 7.5 at 20° C.

[0149] The submicron particle may comprise a second payload molecule. The second payload molecule is preferably encapsulated in the lipid structure. Alternatively or additionally, the second payload molecule may be covalently conjugated and / or physically attached to the outer surface of the lipid structure. The first payload molecule and the second payload molecule may be of different types, species or structures.

[0150] The second payload molecule may preferably be an active pharmaceutical ingredient (API) or a component thereof, or a facilitator or enabler thereof, such as an enzyme (e.g., CRISPR-Cas9, etc.). The second payload molecule may be a hydrophobic or hydrophilic second payload molecule. The second payload molecule may be a macromolecule or a small molecule.

[0151] It may be appreciated that a small molecule may be considered to be a molecule having a molecular weight of less than 900 Daltons. In some embodiments, a small molecule may have a molecular weight of less than 800 Daltons, less than 700 Daltons, less than 600 Daltons, less than 500 Daltons, or less than 400 Daltons.

[0152] Any small molecule drug, defined as a low molecular weight chemical entity, can be used as the second payload molecule.For example, anticancer drugs and anti-inflammatory drugs, such as steroids, can be used.Additional examples can include ruxolitinib and other Janus kinase inhibitors, doxorubicin, tofacitinib, curcumin, paclitaxel, cisplatin, buprenorphine, aspirin, ibuprofen, or naproxen, etc.

[0153] Advantageously, the present inventors have demonstrated that submicron particles are capable of co-delivering macromolecules, such as nucleic acids, and a second payload molecule.

[0154] Submicron particle may further comprise at least one stabilizing molecule. At least one stabilizing molecule may be encapsulated in lipid structure. Alternatively or additionally, at least one stabilizing molecule may be located on the outside of lipid structure. In some embodiments, at least one stabilizing molecule on the outside of lipid structure may be covalently conjugated and / or physically attached to the outer surface of lipid structure.

[0155] The or each stabilising molecule may be a carbohydrate and / or a polyol.

[0156] Carbohydrates may be referred to as sugars. Carbohydrates may be monosaccharides or pharmaceutically acceptable complexes, salts, solvates, tautomeric forms, stereoisomers or polymorphic forms thereof, which may be selected from the group consisting of glucose; galactose; fructose; mannose; and xylose. Alternatively, carbohydrates may be disaccharides or pharmaceutically acceptable complexes, salts, solvates, tautomeric forms, stereoisomers or polymorphic forms thereof, which may be selected from the group consisting of trehalose; sucrose; lactose; maltose; isomaltose; lactitol; lactulose; mannobiose; and isomalt. In a further alternative, carbohydrates may be trisaccharides or pharmaceutically acceptable complexes, salts, solvates, tautomeric forms, stereoisomers or polymorphic forms thereof, which may be selected from the group consisting of nigerotriose; maltotriose; melezitose; maltotriulose; raffinose; and kestose. In a further alternative, the carbohydrate may be a polysaccharide, which may be selected from the group consisting of dextran; amylose; amylopectin; glycogen; galactogen; inulin; callose; cellulose; chitosan; and chitin, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof.

[0157] The carbohydrate may be a polyol, which may be selected from the group consisting of sorbitol; mannitol; glycerol; alpha-D-glucopyranosyl-1-6-sorbitol; alpha-D-glucopyranosyl-1-6-mannitol; malto-oligosaccharides; hydrogenated malto-oligosaccharides, starch and cellulose, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof.

[0158] Alternatively or additionally, the polyol can be an oligomer containing multiple hydroxyl groups; a polymer containing multiple hydroxyl groups; or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof.

[0159] The at least one stabilizing molecule may include at least two different stabilizing molecules. Each stabilizing molecule may be a carbohydrate. In one embodiment, the first stabilizing molecule may be a disaccharide (e.g., trehalose) and the second stabilizing molecule may be a polysaccharide (e.g., dextran).

[0160] In some embodiments, the carbohydrate is a disaccharide, most preferably trehalose, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomeric form or polymorphic form thereof. The trehalose may be synthetic or natural trehalose.

[0161] Advantageously, the inventors have surprisingly demonstrated that when the submicron particles contain trehalose, macromolecules such as nucleic acids, both lyophilized and in aqueous solution, can be stabilized for extended periods at room temperature. Moreover, storage at 40° C. is also enhanced. This was completely unexpected.

[0162] Preferably, the submicron particles of the first embodiment are thermally stabilized.

[0163] It will be appreciated that the term "thermostabilization" or "thermally stabilized" can mean that the submicron particle substantially retains its biological activity (e.g., induces an immune response and / or protein expression in a subject to which it is administered) when stored at a certain temperature for a certain period of time. The inventors do not wish to be bound by any hypothesis, but believe that the thermostabilization effect can be achieved by stabilizing lipid structures in the formulation, for example by preventing or reducing its aggregation; by minimizing payload leakage; by stabilizing the payload molecule (preferably RNA) itself; and / or by stabilizing the submicron particle to improve colloidal stability. Whether or to what extent the functional activity of the payload molecule (preferably RNA) is retained can be determined, for example, by detecting the presence of immune-specific antibodies (e.g., IgG) against the antigen of interest encoded by the RNA construct and / or by detecting the expression of the protein of interest.

[0164] Preferably, the submicron particles are thermally stabilized after storage at temperatures above -100°C, above -80°C, above -60°C, above -40°C or above -20°C, more preferably above -15°C, and most preferably above -10°C. Preferably, the submicron particles are thermally stabilized after storage at temperatures above -5°C, more preferably above 0°C, and most preferably above 1°C. Most preferably, the submicron particles are thermally stabilized after storage at temperatures above 2°C, more preferably above 3°C, and most preferably above 4°C. Even more preferably, the submicron particles are thermally stabilized after storage at temperatures above 5°C, more preferably above 6°C, and most preferably above 7°C.

[0165] The submicron particles may be thermally stabilized after storage at temperatures below 100° C., below 80° C., below 60° C., below 50° C., below 40° C., below 35° C., or below 30° C. The submicron particles may be thermally stabilized after storage at temperatures below 25° C., below 20° C., or below 15° C. The submicron particles may be thermally stabilized after storage at temperatures below 10° C., below 8° C., or below 7° C.

[0166] The submicron particles may be thermally stabilized after storage at temperatures between -100°C and 100°C, between -80°C and 90°C, between -60°C and 80°C, between -40°C and 70°C, between -20°C and 60°C, between -20°C and 50°C, between -20°C and 40°C, between -20°C and 35°C, between -20°C and 30°C, between -15°C and 25°C, or between -10°C and 20°C. The submicron particles may be thermally stabilized after storage at temperatures between -5°C and 15°C, between 0°C and 10°C, between 1°C and 9°C, or between 2°C and 8°C.

[0167] The submicron particle may include at least one targeting ligand or moiety. At least one targeting ligand or moiety may be disposed on the outer surface of the submicron particle. Thus, at least one targeting ligand or moiety may be disposed on the outer surface of the lipid structure and / or on the amphiphilic polymer chain.

[0168] The at least one targeting ligand or moiety may be or may include at least one of a peptide, a protein, an aptamer, a carbohydrate, an oligosaccharide, folic acid or folate, and an antibody or an antigen-binding fragment thereof, a vitamin or a derivative thereof. The peptide may be a G protein-coupled receptor (GCR), Arg-Gly-Asp (RGD), or a derivative thereof. The protein may be a lectin, transferrin, or a derivative thereof. The aptamer may be an RNA aptamer against HIV glycoprotein, or a derivative thereof. The carbohydrate may be as defined above. In particular, the carbohydrate may be mannose, glucose, galactose, or a derivative thereof. The antibody may be monoclonal or polyclonal. The antibody may be an anti-Her2 antibody, an anti-EGFR antibody, or a derivative thereof. The vitamin may be vitamin D.

[0169] The present inventors have devised a novel method for producing the payload delivery system and submicron particles of the present invention.

[0170] Thus, according to a second aspect, there is provided a method for producing a submicron particle, the method comprising combining a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains to produce a submicron particle, the first payload molecule being a macromolecule, optionally a nucleic acid, and the hydrophilicity of the amphiphilic polymer chains being altered in response to an external stimulus.

[0171] Preferably, the method of the second aspect produces the submicron particles of the first aspect.

[0172] Advantageously, and preferably, the method of the second aspect may be used to modify existing lipid structures, including lipid nanoparticles and liposomal systems.

[0173] The first payload molecule, the lipid structure (comprising a plurality of lipids) and the plurality of amphiphilic polymer chains may be as defined in relation to the first embodiment.

[0174] The first payload molecule may be covalently conjugated and / or physically attached to the outer surface of the lipid structure. Preferably, the first payload molecule is encapsulated in the lipid structure.

[0175] Thus, the method may include contacting a first payload molecule with a plurality of lipids to produce a lipid structure encapsulating the first payload molecule, and then contacting the lipid structure with a plurality of amphiphilic polymer chains to produce a submicron particle.

[0176] In some embodiments, the method may include contacting a first payload molecule, a second payload molecule, and a plurality of lipids to produce a lipid structure that encapsulates the first and second payload molecules or is covalently conjugated and / or physically attached on its outer surface to the first and second payload molecules; and then contacting the lipid structure with a plurality of amphiphilic polymer chains to produce the submicron particle.

[0177] The second payload molecule is preferably encapsulated in the lipid structure. Alternatively, the second payload molecule may be covalently conjugated and / or physically attached to the outer surface of the lipid structure. The second payload molecule is preferably different from the first payload molecule, i.e., different in terms of being of different type, species or chemical structure.

[0178] In some embodiments, the method may include contacting a first payload molecule, at least one stabilizing molecule and a plurality of lipids to produce a lipid structure containing the first payload molecule and at least one stabilizing molecule; and then contacting the lipid structure with a plurality of amphiphilic polymer chains to produce submicron particles. The first payload molecule is preferably encapsulated in the lipid structure. Alternatively, the first payload molecule may be covalently conjugated and / or physically attached to the outer surface of the lipid structure. The at least one stabilizing molecule may be encapsulated in the lipid structure. Alternatively or additionally, the at least one stabilizing molecule may be located on the outside of the lipid structure.

[0179] In some embodiments, the method may include contacting a first payload molecule, a second payload molecule, at least one stabilizing molecule and a plurality of lipids to produce a lipid structure containing the first and second payload molecules and at least one stabilizing molecule; and then contacting the lipid structure with a plurality of amphiphilic polymer chains to produce submicron particles. The first payload molecule and the second payload molecule are preferably encapsulated in the lipid structure. Alternatively, the first and / or second payload molecule may be covalently conjugated and / or physically attached to the outer surface of the lipid structure. At least one stabilizing molecule may be encapsulated in the lipid structure. Alternatively or additionally, at least one stabilizing molecule may be located on the outside of the lipid structure.

[0180] Contacting the first payload molecule with the plurality of lipids to form lipid structures may include contacting the first payload molecule with a lipid membrane comprising the plurality of lipids in a solution and extruding the solution to produce lipid structures encapsulating the first payload molecule. It will be appreciated that in embodiments where they are present, the second payload molecule and / or at least one stabilizing molecule may contact the first payload and lipid membrane in a solution and then be encapsulated in the lipid structure. The solution may include water. The solution may include a buffer. Preferably, the solution is substantially free of RNAse. The solution may include disodium hydrogen phosphate and / or sodium chloride. In some embodiments, phosphate buffered saline (PBS), more preferably Dulbecco's phosphate buffered saline (DPBS), is used.

[0181] The method may include extruding the solution through a membrane. The membrane may have a size between 0.005-50 μm, between 0.01-10 μm, between 0.05-5 μm, between 0.1-3 μm, or between 0.15-0.25 μm. The method may include extruding the solution between 1-10,000 times, between 5-1,000 times, between 10-500 times, between 15-250 times, between 20-100 times, between 25-50 times, or between 28-35 times.

[0182] The method may include contacting a lipid structure with a plurality of amphiphilic polymer chains in a solution. The solution may include water. The solution may include a buffer. Preferably, the solution is substantially free of RNAse. The solution may include disodium hydrogen phosphate and / or sodium chloride. In some embodiments, phosphate buffered saline (PBS), more preferably Dulbecco's phosphate buffered saline (DPBS), is used.

[0183] The method may comprise contacting the lipid structure with the plurality of amphiphilic polymer chains for at least 30 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 8 hours, or at least 12 hours.

[0184] The method can include removing excess polymer chains. The excess polymer chains can be removed using dialysis, centrifugation, or ultracentrifugation.

[0185] The inventors believe that the submicron particles of the present invention are themselves novel.

[0186] Thus, according to a third aspect, there is provided a submicron particle obtained or obtainable by the method of the second aspect.

[0187] According to a fourth aspect, there is provided a composition comprising a plurality of submicron particles of the first or third aspect.

[0188] In some embodiments, the composition is a pharmaceutical composition and includes a pharma- ceutically acceptable vehicle.

[0189] The composition may include a solvent. The solvent may include a buffer. Preferably, the solvent is substantially free of RNAse. It is preferable to use a buffer or saline solution, such as Dulbecco's Phosphate Buffered Saline (DPBS), HEPES buffered saline, Tris buffered saline or other such cell culture compatible buffers. This is because ions provide additional stability to the composition.

[0190] Submicron particles are 1×10 3 ~1×10 20 Between 1 x 10 particles / ml 5 ~1×10 15 Between 1 x 10 particles / ml 7 ~1×10 11 Between 1 x 10 particles / ml 8 ~1×10 10 Between 1 x 10 particles / ml 9 ~5×10 9 Between 2 x 10 particles / ml 9 ~4×10 9 Between 2.5 x 10 particles / ml 9 ~3.5×10 9 Between 2.8 x 10 particles / ml 9 ~3×10 9The particles may be present in a concentration between 100 and 2000 particles / ml.

[0191] In embodiments in which the submicron particles comprise at least one stabilizing molecule, the at least one stabilizing molecule may be present in a concentration of between 1-5000 mg / ml, between 10-4000 mg / ml, between 20-3000 mg / ml, between 30-2000 mg / ml, between 40-1000 mg / ml, between 50-750 mg / ml, between 60-500 mg / ml, between 80-400 mg / ml, between 100-350 mg / ml, or between 200-300 mg / ml.

[0192] In embodiments in which the submicron particles comprise at least one stabilizing molecule, the at least one stabilizing molecule may be present in a concentration of between 10-900 mg / ml, between 20-800 mg / ml, between 30-700 mg / ml, between 40-600 mg / ml, between 50-500 mg / ml, between 60-450 mg / ml, between 80-400 mg / ml, between 100-350 mg / ml, or between 200-300 mg / ml.

[0193] Alternatively, the composition of the fourth aspect may be solvent-free. Thus, the composition may be freeze-dried, vacuum-dried, air-dried or spray-dried. More preferably, the composition may be freeze-dried.

[0194] In a fifth aspect, there is provided a method of preparing a pharmaceutical composition comprising contacting a plurality of submicron particles of the first or third aspect with a pharma- ceutically acceptable vehicle.

[0195] In a sixth aspect, there is provided a submicron particle of the first or third aspect, or a composition of the fourth aspect, for use as a medicament.

[0196] In a seventh aspect, there is provided a method of treatment comprising administering or having administered a therapeutic amount of the submicron particles of the first or third aspect, or the composition of the fourth aspect, to a subject in need thereof.

[0197] In an eighth aspect there is provided a vaccine composition comprising the submicron particles of the first or third aspect, or the composition of the fourth aspect.

[0198] The vaccine may contain a suitable adjuvant.

[0199] In a ninth aspect, there is provided a submicron particle of the first or third aspect, a composition of the fourth aspect or a vaccine of the eighth aspect for use in stimulating an immune response in a subject.

[0200] The immune response may be stimulated against a protozoan, a bacterium, a virus, a fungus or a cancer.

[0201] In a tenth aspect of the invention there is provided a method of vaccinating a subject comprising administering, or having administered, a therapeutic amount of submicron particles of the first or third aspect, a composition of the fourth aspect or a vaccine of the eighth aspect to a subject in need thereof.

[0202] The submicron particles, compositions or vaccines of the present invention can be combined into compositions having several different forms, depending in particular on the method in which the composition is used.Thus, for example, the composition can be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micelle solution, transdermal patch, liposomal suspension or any other suitable form that can be administered to a person or animal in need of treatment.It will be appreciated that the pharmaceutical vehicle according to the present invention should be one that is well tolerated by the subject to which it is given.

[0203] The submicron particles, compositions or vaccines of the present invention may also be incorporated into sustained or delayed release devices. Such devices may, for example, be inserted on or under the skin, and the drug may be released over a period of weeks or even months. The devices may be placed at least adjacent to the treatment site.

[0204] However, in a preferred embodiment, the medicament according to the invention may be administered to a subject by injection into the bloodstream, muscle, skin or directly into the area requiring treatment. The injection may be intravenous (bolus or infusion), subcutaneous (bolus or infusion), intradermal (bolus or infusion), intramuscular (bolus or infusion), intrathecal (bolus or infusion), epidural (bolus or infusion) or intraperitoneal (bolus or infusion).

[0205] It will be appreciated that the amount of submicron particle, composition or vaccine required will be determined by its biological activity and bioavailability, which will depend on the mode of administration, the physiochemical properties of the submicron particle, composition or vaccine, and whether it is used as a monotherapy or in a combination therapy.

[0206] The frequency of administration is also influenced by the half-life of the active agent in the subject being treated.The optimal dosage to be administered can be determined by those skilled in the art and varies depending on the submicron particles, composition or vaccine being used, the strength of the composition, the mode of administration, and the type of treatment.Additional factors depending on the specific subject being treated result in the need to adjust the dosage, including the subject's age, weight, sex, diet, and administration time.

[0207] The dosage required may depend on several factors, including but not limited to, the active agent being administered, the disease being treated and / or vaccinated against, the subject being treated, and the like.

[0208] Generally, depending on the active agent used, a dose of between 0.001 μg / kg body weight and 10 mg / kg body weight or between 0.01 μg / kg body weight and 1 mg / kg body weight of the submicron particles, compositions or vaccines of the invention may be used. It will be understood that the dose relates to the amount of payload molecule delivered.

[0209] The dose may be given as a single administration (e.g., a single injection). Alternatively, the submicron particles, compositions or vaccines may require two or more administrations. By way of example, the submicron particles, compositions or vaccines may be administered as two or more doses of between 0.07 μg and 700 mg (i.e., assuming a body weight of 70 kg). Alternatively, a sustained release device may be used to provide an optimal dose of the submicron particles, compositions or vaccines according to the invention to the patient without the need to administer repeated doses. The route of administration may incorporate intravenous, intradermal, subcutaneous, intramuscular, intrathecal, epidural or intraperitoneal injection routes.

[0210] Known procedures, such as those routinely employed by the pharmaceutical industry (e.g., in vivo experiments, clinical trials, etc.), can be used to form the particular formulation of the submicron particles, compositions or vaccines according to the invention, and the precise treatment regime (such as drug dose and frequency of administration).

[0211] A "subject" may be a vertebrate, a mammal, or a domestic animal. Thus, the compositions and medicaments according to the present invention may be used to treat any mammal, for example, livestock (e.g., horses), pets, or other veterinary uses. However, most preferably, the subject is a human.

[0212] A "therapeutically effective amount" of a submicron particle, composition or vaccine is any amount, as described above, necessary to produce a therapeutic effect when administered to a subject.

[0213] For example, a therapeutically effective amount of the submicron particles, compositions and vaccines of the present invention may contain from about 0.001 mg to about 800 mg of the payload molecule, preferably from about 0.01 mg to about 500 mg of the payload molecule.

[0214] A "pharmaceutically acceptable vehicle" as referred to herein is any known compound or combination of known compounds known to those of ordinary skill in the art to be useful in formulating a composition.

[0215] In one embodiment, the pharma- ceutically acceptable vehicle can be solid, and the composition can be in the form of a powder, capsule, or tablet. The solid pharma- ceutically acceptable vehicle can include one or more substances that can also act as flavoring agents, lubricants, solubilizers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coating agents, or tablet disintegrants. The vehicle can also be an encapsulating material. In a powder, the vehicle is a fine solid mixed with the fine active agent according to the present invention. In a tablet, the active agent (e.g., the submicron particles of the present invention) can be mixed with a vehicle with the necessary compression properties in the appropriate proportions and compressed into the desired shape and size. The pharmaceutical vehicle can be a gel, and the composition can be in the form of a cream, etc.

[0216] Alternatively, the pharmaceutical vehicle may be liquid and the composition is in the form of a solution. Liquid vehicles are used in the preparation of solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The submicron particles according to the present invention may be dissolved or suspended in a pharma- ceutically acceptable liquid vehicle, such as water, an organic solvent, a mixture of both, or a pharma- ceutically acceptable oil or fat. The liquid vehicle may contain other suitable pharmaceutical additives, such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavorings, suspending agents, thickeners, colorants, viscosity adjusters, stabilizers or osmolality adjusters. Suitable examples of liquid vehicles for oral and parenteral administration include water (partially containing additives as described above, e.g., cellulose derivatives, preferably sodium carboxymethylcellulose solution), alcohols (including monohydric and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and peanut oil). For parenteral administration, the vehicle may be an oily ester, such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for parenteral administration. The liquid vehicle for pressurized compositions can be halogenated hydrocarbon or other pharma- ceutically acceptable propellant.

[0217] Liquid pharmaceutical compositions that are sterile solutions or suspensions can be utilized by, for example, intramuscular, intrathecal, epidural, intraperitoneal, intravenous and subcutaneous injection. The submicron particles of the present invention can be prepared in any suitable sterile injectable medium.

[0218] The submicron particles can be administered by inhalation, for example, the submicron particles can be provided in the form of an aerosol.

[0219] The submicron particles and / or compositions of the invention may be orally administered in the form of a sterile solution or suspension containing other solutes or suspending agents (e.g., sufficient saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleic acid ester of sorbitol and its anhydride copolymerized with ethylene oxide), and the like. The submicron particles and / or compositions of the invention may also be orally administered in either liquid or solid composition form. Compositions suitable for oral administration include solid forms such as pills, capsules, granules, tablets, and powders, and liquid forms such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.

[0220] All of the features described in this specification (including any accompanying claims, abstract, and drawings), and / or all of the steps of any method or process so disclosed may be combined with any of the above aspects in any combination, except combinations where at least some of such features and / or steps are mutually exclusive.

[0221] For a better understanding of the present invention, and to show how embodiments thereof may be carried into effect, reference will now be made, by way of example, to the accompanying drawings in which: [Brief description of the drawings]

[0222] [Figure 1]FIG. 1 is a schematic diagram of polymer-functionalized lipid nanoparticles (PF-LNPs) and PF-LNP-mediated intracellular delivery of RNA, including messenger RNA (mRNA) or self-amplifying RNA (saRNA). [Diagram 2] Graphs showing the coating density of PP75 after dialysis to remove excess polymer [A] and the coating efficiency of PP75 based on density on the surface of LNPs [B] when various concentrations of anionic, viral peptidomimetic, membrane-permeabilizing pseudopeptide polymer PP75 were added to LNPs (DOTAP / DOPE weight ratio = 1:1, 40 wt% cholesterol), mean ± SD (n = 3). [Diagram 3] Physiochemical characterization of PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and various PP75 polymer coating densities) at pH 7.4: Mean hydrodynamic diameter [A], nanoparticle tracking analysis (NTA) measurements of size distribution, particle concentration and PDI values ​​[B], and zeta potential measurements [C]. Mean ± SD (n=3). [Figure 4] Figure 1 shows the effect of cholesterol content (at a fixed PP75 density of 1.0x104 polymer chains / particle) [A] and polymer coating density (at a fixed cholesterol content of 40 wt%) [B] on saRNA encapsulation efficiency in PF-LNPs (DOTAP / DOPE=1:1) as determined by RiboGreen™ assay. Mean ± SD (n=3). [Diagram 5]Figure 1 shows the relative HeLa cell viability after 4, 8, 24 and 48 hours of incubation with saRNA-encapsulated PF-LNPs (DOTAP / DOPE=1:1, 40% by weight cholesterol and various PP75 coating densities) as determined by Alamar Blue assay [A]. The relative HeLa cell viability after 24 hours of incubation with PF-LNPs (DOTAP / DOPE=1:1, 40% by weight cholesterol and various PP75 coating densities) with and without encapsulated saRNA as determined by Alamar Blue assay [B]. The relative HeLa cell viability after 24 hours of incubation with PF-LNPs (DOTAP / DOPE=1:1, 40% by weight cholesterol and various PP75 coating densities) with and without encapsulated saRNA as determined by LDH assay [C]. N / P ratio=1. Mean±SD (n=3). [Figure 6] Relative hemolysis of red blood cells (RBCs) after 1 h of incubation with PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and various PP75 coating densities) with [A] and without [B] saRNA at various pH values. N / P ratio=1. Mean ± SD (n=3). [Figure 7] Figure 1 shows HEK-293 cell transfection after 4 h of incubation with PF-LNPs (N / P ratio = 1, PEI as control) consisting of DOTAP / DOPE at weight ratios of 1:1 [A], 1:2 [B] and 1:4 [C], various percentages of cholesterol, and various coating densities of PP75 as determined by firefly luciferase (fLuc) assay. Luciferase expression was assessed 24 h after transfection and expressed as relative light units (RLU). Mean ± SD (n = 3). [Figure 8]Figure 1 shows HEK-293 cells transfection after 3 h of incubation with PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and various PP75 coating densities) with N / P ratios of 0.1, 1 and 10, respectively, as determined by firefly luciferase (fLuc) assay. Luciferase expression was assessed 24 h after transfection and expressed as relative light units (RLU). Mean ± SD (n=3). *p<0.05, **p<0.01, ***p<0.001. [Figure 9] Figure 1 shows Hela cell transfection after 3 hours of incubation with PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and 1.3x104 PP75 polymer chains / particle) with various concentrations of saRNA as determined by firefly luciferase (fLuc) assay. Luciferase expression was assessed 24 hours after transfection and expressed as relative light units (RLU). N / P ratio=1. Mean±SD (n=3). [Figure 10] FIG. 1 provides laser scanning confocal microscopy images [A] of enhanced green fluorescent protein-encoding saRNA (EGFP-saRNA)-encapsulated PF-LNPs (N / P ratio=1) coated with PP75 at 1.3×104 polymer strands / particle and quantitative representations [B] of HEK-293 cells upon incubation with various pathway inhibitors. [Figure 11]FIG. 1 provides in vivo visualization of fLuc bioluminescence in Balb / C female mice 7 days after intramuscular injection of 5 μg fLuc saRNA per leg. Images show (from left to right) saRNA only, saRNA / PEI complex, saRNA-encapsulated LNPs without PP75 functionalization (DOTAP / DOPE=1:1, 40% cholesterol by weight), and saRNA-encapsulated PF-LNPs composed of DOTAP / DOPE (1:1), 40% cholesterol by weight, and PP75 densities of 1.0×104 and 1.3×104 polymer chains / particle, respectively [A]. Quantification of luciferase expression by lines at mean ± standard deviation for n=5 mice (n=10 legs) per group [B]. N / P ratio=1. *p<0.05. [Figure 12-1] Figure 1 shows in vivo evaluation of immunogenicity of PF-LNPs encapsulating hemagglutinin influenza virus-encoded saRNA (HA-saRNA) in Balb / C female mice over a 6-week period: antibody titers after immunization with HA-saRNA encapsulated in jetPEI-complexed and naive PF-LNPs as determined by ELISA for n=5 mice at each time point [A], mouse survival [B], and percentage body weight of mice over the study period [C]. [Figure 12-2] Figure 1 shows in vivo evaluation of immunogenicity of PF-LNPs encapsulating hemagglutinin influenza virus-encoded saRNA (HA-saRNA) in Balb / C female mice over a 6-week period: antibody titers after immunization with HA-saRNA encapsulated in jetPEI-complexed and naive PF-LNPs as determined by ELISA for n=5 mice at each time point [A], mouse survival [B], and percentage body weight of mice over the study period [C]. [Figure 13]This is a diagram showing lymphatic vessels in mouse lymph nodes 1 hour after administration of only saRNA encoding EGFP [A], EGFP-saRNA encapsulated in PF-LNPs coated with 1.0×104 polymer strands / particle Cy5-PP75 [B], and EGFP-saRNA encapsulated in PF-LNPs coated with 1.3×104 polymer strands / particle Cy5-PP75 [C]. Fluorescent images show EGFP-saRNA expression. [Figure 14] Figure 1 shows the effect of ruxolitinib concentration co-delivered with LNPs without polymer functionalization (DOTAP / DOPE=1:1, 40 wt% cholesterol) and PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and 1.3x104 PP75 polymer chains / particle) on saRNA encapsulation efficiency as determined by RiboGreen™ assay. (N / P ratio=1, PEI as control). Mean ± SD (n=3). [Figure 15] Figure 1 shows the effect of ruxolitinib concentration co-delivered with LNPs without polymer functionalization (DOTAP / DOPE 1:1, 40 wt% cholesterol) and PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and 1.3x104 PP75 polymer chains / particle) on MRC-5 cell transfection (N / P ratio=1, PEI as control). Mean ± SD (n=3). [Figure 16] Figure 1 provides an evaluation of the aqueous and lyophilized formulation of saRNA-encapsulated PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and 1.3x104 PP75 polymer chains / particle) with trehalose coexisting both inside and outside of the PF-LNPs. Hydrodynamic size and polydispersity index (PDI) of the formulations [A], Zeta potential [B], and HEK-293 cell transfection of saRNA determined by firefly luciferase (fLuc) assay [C]. (N / P ratio=1). Mean ± SD (n=3). [Figure 17]Figure 1 shows the relative HEK-293 cell viability after 24 and 48 h of incubation with aqueous [A] and lyophilized [B] formulations of saRNA-encapsulated PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol and 1.3×104 PP75 polymer chains / particle) with coexisting trehalose both inside and outside the PF-LNPs as determined by Alamar Blue assay. N / P ratio=1. [Figure 18] FIG. 1 is a schematic showing the interaction of trehalose with RNA-encapsulated PF-LNPs in solution and after lyophilization. [Figure 19] FIG. 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PF-LNPs coated with 1.3×104 PP75 polymer chains / particle with trehalose coexisting both inside and outside the PF-LNPs. Hydrodynamic size and polydispersity index (PDI) of the formulations over 52 weeks of storage at -20°C, 4°C, 20°C and 40°C, respectively. (N / P ratio=1). Mean±SD (n=3). [Figure 20] FIG. 13 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PF-LNPs coated with 1.3×104 PP75 polymer chains / particle with trehalose coexisting both inside and outside the PF-LNP. Zeta potential of the formulations over 52 weeks of storage at -20°C, 4°C, 20°C and 40°C, respectively. (N / P ratio=1). Mean±SD (n=3). [Figure 21] FIG. 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PF-LNPs coated with 1.3×104 PP75 polymer chains / particle with trehalose coexisting both inside and outside the PF-LNPs. HEK-293 cell transfection of saRNA over 52 weeks of storage at −20° C., 4° C., 20° C. and 40° C., respectively, as determined by firefly luciferase (fLuc) assay. (N / P ratio=1). Mean±SD (n=3). [Figure 22]Figure 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PF-LNPs coated with 1.3x104 PP75 polymer chains / particle with coexistence of trehalose both inside and outside the PF-LNPs. Relative cell viability of HEK-293 cells after 48 hours of treatment with the formulations over 52 weeks of storage at -20°C, 4°C, 20°C and 40°C, respectively, measured using the Alamar Blue assay. (N / P ratio=1). Mean ± SD (n=3). [Figure 23] Physiochemical characterization of PEGylated PF-LNPs (DOTAP / DOPE / DMG-PEG2000 / Cholesterol and various PP75 polymer coating densities) at pH 7.4: Mean hydrodynamic diameter and PDI values ​​[A] and Zeta potential [B] of the formulations in aqueous solution and lyophilized form. Mean ± SD (n=3). [Figure 24] Figure 1 shows the encapsulation efficiency of calcein and FITC-dextran (Mw=150 kDa) in PEGylated LNPs (DOTAP / DOPE / DMG-PEG2000 / cholesterol) [A] and the encapsulation efficiency of fLuc-saRNA [B] as determined by RiboGreen assay. [Diagram 25] FIG. 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PEGylated PF-LNPs (DOTAP / DOPE / DMG-PEG2000 / cholesterol+1mg / mL PP75) with trehalose coexisting both inside and outside the PEGylated PF-LNPs. Hydrodynamic size and polydispersity index (PDI) of the formulations over 9 weeks of storage at -20°C, 4°C, 20°C and 40°C, respectively. (N / P ratio=1). Mean±SD (n=3). [Figure 26] FIG. 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PEGylated PF-LNPs (DOTAP / DOPE / DMG-PEG2000 / cholesterol+1mg / mL PP75) with trehalose coexisting both inside and outside the PEGylated PF-LNPs. Zeta potential of the formulations over 9 weeks of storage at -20°C, 4°C, 20°C and 40°C, respectively. (N / P ratio=1). Mean±SD (n=3). [Figure 27] FIG. 1 provides an evaluation of storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PEGylated PF-LNPs (DOTAP / DOPE / DMG-PEG2000 / Cholesterol+1mg / mL PP75) with trehalose coexisting both inside and outside of the PEGylated PF-LNPs. HEK-293 cell transfection of saRNA over 9 weeks of storage at -20°C, 4°C, 20°C and 40°C, respectively, as determined by firefly luciferase (fLuc) assay. (N / P ratio=1). Mean ± SD (n=3). [Figure 28] FIG. 1 provides an evaluation of storage stability of aqueous and lyophilized formulations of saRNA-encapsulated PEGylated PF-LNPs (DOTAP / DOPE / DMG-PEG2000 / cholesterol+1mg / mL PP75) with trehalose coexisting both inside and outside of the PEGylated PF-LNPs. Relative cell viability of HEK-293 cells after 48 hours of treatment with the formulations over 9 weeks of storage at -20°C, 4°C, 20°C and 40°C, respectively, measured using the Alamar Blue assay. (N / P ratio=1). Mean±SD (n=3). [Figure 29] Figure 14. Physiochemical characterization (mean hydrodynamic diameter, PDI values ​​and zeta potential) of MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing various concentrations of PP75[A], PLP-NDA[B] and PLP-ADA[C] polymers at pH 7.4 without saRNA: Mean ± SD (n=3). [Diagram 30] Figure 1. Physiochemical characterization (mean hydrodynamic diameter, PDI values ​​and zeta potential) of MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing saRNA and various concentrations of PP75[A], PLP-NDA[B] and PLP-ADA[C] polymers at pH 7.4: Mean ± SD (n=3). [Diagram 31]Figure 1 shows the encapsulation efficiency of calcein and FITC-dextran (Mw=150 kDa) in MC3 LNPs (MC3 / DSPC / Chol / DMG-PEG2000) [A] and the encapsulation efficiency of fLuc-saRNA determined by RiboGreeen assay [B]. [Diagram 32] Figure 1 shows HEK-293 cell transfection of saRNA encapsulated in MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing various concentrations of PP75, PLP-NDA and PLP-ADA polymers as determined by firefly luciferase (fLuc) assay (N / P ratio=1). Mean ± SD (n=3). [Diagram 33] Figure 1 shows the relative cell viability of HEK-293 cells after 48 h treatment with saRNA encapsulated in MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing various concentrations of PP75, PLP-NDA and PLP-ADA polymers as measured using the Alamar Blue assay (N / P ratio=1). Mean ± SD (n=3). [Diagram 34] Figure 1 shows physiochemical characterization (mean hydrodynamic diameter and PDI values ​​[A] and zeta potential [B]) of MC3 LNPs (MC3 / DSPC / Chol / DMG-PEG2000) without saRNA and at various pH values: mean ± SD (n=3). [Diagram 35] Figure 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing 1 mg / mL PP75, PLP-NDA, or PLP-ADA with trehalose coexisting both inside and outside the MC3 PF-LNPs. Hydrodynamic size and polydispersity index (PDI) of the formulations over 11 weeks of storage at -20°C, 4°C, and 20°C, respectively. (N / P ratio=1). Mean ± SD (n=3). [Diagram 36]FIG. 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing 1 mg / mL PP75, PLP-NDA, or PLP-ADA with trehalose coexisting both inside and outside the MC3 PF-LNPs. Zeta potential of the formulations over 11 weeks of storage at -20°C, 4°C, and 20°C, respectively. (N / P ratio=1). Mean ± SD (n=3). [Figure 37] Figure 1 provides an evaluation of storage stability of aqueous and lyophilized formulations of saRNA-encapsulated MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing 1 mg / mL PP75, PLP-NDA, or PLP-ADA with trehalose coexisting both inside and outside of MC3 PF-LNPs. HEK-293 cell transfection of saRNA over 11 weeks of storage at -20°C, 4°C, and 20°C, respectively, as determined by firefly luciferase (fLuc) assay. (N / P ratio=1). Mean ± SD (n=3). [Figure 38] Figure 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated MC3 PF-LNPs (MC3 / DSPC / Chol / DMG-PEG2000) containing 1 mg / mL PP75, PLP-NDA, or PLP-ADA with trehalose coexisting both inside and outside of MC3 PF-LNPs. Relative cell viability of HEK-293 cells after 48 h treatment with the formulations over 11 weeks of storage at -20°C, 4°C, and 20°C, respectively, measured using the Alamar Blue assay. (N / P ratio=1). Mean ± SD (n=3). [Figure 39] Figure 1. Physiochemical characterization (mean hydrodynamic diameter, PDI values ​​and zeta potential) of DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing saRNA and various concentrations of PP75[A], PLP-NDA[B] and PLP-ADA[C] polymers at pH 7.4: Mean ± SD (n=3). [Diagram 40]Figure Physiochemical characterization (mean hydrodynamic diameter, PDI values ​​and zeta potential) of DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing saRNA and various concentrations of PP75[A], PLP-NDA[B] and PLP-ADA[C] polymers at pH 7.4: Mean ± SD (n=3). [Diagram 41] Figure 1 shows the encapsulation efficiency of calcein and FITC-dextran (Mw=150 kDa) in DODAP LNPs (DODAP / DOPE / Chol / DMG-PEG2000) [A] and the encapsulation efficiency of fLuc-saRNA determined by RiboGreeen assay [B]. [Diagram 42] Figure 1 shows HEK-293 cell transfection of saRNA encapsulated in DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing various concentrations of PP75, PLP-NDA and PLP-ADA polymers as determined by firefly luciferase (fLuc) assay (N / P ratio=1). Mean ± SD (n=3). [Diagram 43] Figure 1 shows the relative cell viability of HEK-293 cells after 48 h treatment with saRNA encapsulated in DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing various concentrations of PP75, PLP-NDA and PLP-ADA polymers as measured using the Alamar Blue assay (N / P ratio=1). Mean ± SD (n=3). [Diagram 44] Figure 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing 1 mg / mL PP75, PLP-NDA, or PLP-ADA with trehalose coexisting both inside and outside the DODAP PF-LNPs. Hydrodynamic size and polydispersity index (PDI) of the formulations over 11 weeks of storage at -20°C, 4°C, and 20°C, respectively. (N / P ratio=1). Mean ± SD (n=3). [Diagram 45]Figure 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing 1 mg / mL with trehalose coexisting both inside and outside of DODAP PF-LNPs. Zeta potential of the formulations over 11 weeks of storage at -20°C, 4°C, and 20°C, respectively. (N / P ratio=1). Mean ± SD (n=3). [Diagram 46] Figure 1 provides an evaluation of storage stability of aqueous and lyophilized formulations of saRNA-encapsulated DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing 1 mg / mL PP75, PLP-NDA or PLP-ADA with trehalose coexisting both inside and outside of DODAP PF-LNPs. HEK-293 cell transfection of saRNA over 11 weeks of storage at -20°C, 4°C and 20°C, respectively, as determined by firefly luciferase (fLuc) assay. (N / P ratio=1). Mean ± SD (n=3). [Figure 47] Figure 1 provides an evaluation of the storage stability of aqueous and lyophilized formulations of saRNA-encapsulated DODAP PF-LNPs (DODAP / DOPE / Chol / DMG-PEG2000) containing 1 mg / mL PP75, PLP-NDA, or PLP-ADA with trehalose coexisting both inside and outside the DODAP PF-LNPs. Relative cell viability of HEK-293 cells after 48 h treatment with the formulations over 11 weeks of storage at -20°C, 4°C, and 20°C, respectively, measured using the Alamar Blue assay. (N / P ratio=1). Mean ± SD (n=3). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0223] Working Example Example 1 - Preparation and characterization of PF-LNPs, showing high biocompatibility and low cytotoxicity, as well as high in vitro transfection efficiency via efficient intracellular RNA delivery We synthesized polymer-functionalized lipid nanoparticles (PF-LNPs) as described in the Materials and Methods section below. PF-LNPs were coated with a biocompatible, pH-responsive, endosomolytic pseudopeptide polymer called PP75, which mimics the anionic fusion peptide in the hemagglutinin spike of influenza virus.

[0224] PP75 is a pseudopeptide prepared by grafting the hydrophobic amino acid L-phenylalanine to a carboxylic acid pendant on the backbone of poly(L-lysine iso-phthalamide) (PLP), a linear polyamide derived from a metabolite, with a stoichiometric degree of substitution of 75%. The biomimetic anionic amphiphilic polymer contains hydrophobic pendant groups and ionizable carboxylic acid groups found in the fusion peptide of influenza virus. We predicted that PP75 could function as a pseudopeptide on the surface of the particle, mimicking the viral spike and thereby delivering PF-LNP to the cytoplasm via endosomal escape, as shown in Figure 1.

[0225] Polymer Coating Efficiency As shown in Figure 2A, by using 1 mg / mL of PP75, 1.3 × 10 saRNA was encapsulated on the surface of PF-LNPs (DOTAP / DOPE weight ratio = 1:1, 40 wt% cholesterol). 4 It was found that a PP75 polymer density of polymer chains / particle could be obtained. Figure 2B shows that a maximum of 1.0 × 10 4 This indicates that the polymer chains / particles were completely coated on the surface of the PF-LNPs. 4 For polymer chains / particle, the PP75 coating efficiency dropped to only 50.3 ± 0.4%, suggesting that the particle surface was saturated with PP75. For all in vivo studies, a 1.0 × 10 4 ~1.3×10 4 It was decided to focus on PF-LNPs containing polymer chains / particles between

[0226] Physiochemical characterization of PF-LNPs FIG 3A shows the effect of polymer density on the hydrodynamic diameter of PF-LNPs. The average particle size was 0.5×10 4 , 1.0×10 4 and 1.3 × 10 4 For the PP75-coated PF-LNPs, the polymer chains / particles were found to be similar at 110.0 ± 5.6 nm, and the size of the PF-LNPs was consistent with previous studies. 9 It has been demonstrated that particles with a size of 200 nm or less can enter cells through clathrin-coated holes in the cell membrane. 10 Figure 3B shows the concentration and size distribution of the particles. The concentration of PF-LNPs containing 40 wt% cholesterol was 2.9 × 10 9 ±0.7×10 9 particles / mL. The more concentrated the particles, the higher the saRNA dose can be administered in a smaller volume. The particles had a narrow size distribution with a PDI < 0.6 at cholesterol concentrations between 10 and 40 wt%. The charge of the particles, as shown by the zeta potential data in Figure 3C, ranged from +12.0 ± 5.86 mV for PF-LNP without PP75 coating to 1.3 × 10 4 The change from positive to negative charge was 0.5 × 10 4 ~1.0×10 4 Negative charges are generated between polymer chains / particles because they are more efficient at draining to lymph nodes (as demonstrated in Example 4 below) and because they induce high levels of antibody production. 11 This is one of the major advantages of this delivery system, since cationic or ionizable LNPs with positive surface charges, which are widely used for nucleic acid delivery, can impair drainage efficiency to lymph nodes.

[0227] In situ loading of saRNA into PF-LNPs The in situ loading of saRNA into PF-LNPs was also investigated. saRNA (~9500nt) is large and highly negatively charged compared to other nucleic acids such as mRNA. Therefore, it is important to optimize the delivery system to allow for maximum encapsulation efficiency. Figure 4A shows the in situ loading of saRNA into PF-LNPs with 1.0 × 10 saRNA as determined by the RiboGreen™ assay. 4 We show that the saRNA encapsulation efficiency of PF-LNPs coated with polymer chains / particles was dependent on cholesterol content. As cholesterol content increased, the encapsulation efficiency increased. PF-LNPs with 40 wt% cholesterol yielded the highest saRNA encapsulation. This is because cholesterol changes the mechanism by which the polymer and the particle interact; this may affect the stiffness of the system. 9 Without cholesterol, Figure 4A shows a relatively low saRNA encapsulation efficiency. This may be due to the unstable hydrophobic side chains of PP75 in aqueous solution, which are embedded in the nonpolar regions of the lipid membrane. 12 When cholesterol was introduced into the system, the lipid packing became more compact. 13 , making the membrane more rigid 14 This reduces the permeability of the system. 15 , making it possible to achieve higher encapsulation efficiency and reduced leakage at pH 7.4.

[0228] Figure 4B shows the 0.5 x 10 4 , 1.0×10 4 and 1.3 × 10 4 Figure 1 shows the saRNA encapsulation efficiency of PP75-coated PF-LNPs (fixed cholesterol content of 40% by weight) of polymer chains / particles. The encapsulation efficiency was 0.5 × 10 4 The PP75 density of chains / particles peaked at 87.2 ± 9.8%, followed by 1.3 × 10 4The encapsulation efficiency decreased to 51.3 ± 2.4% with increasing PP75 density of polymer chains / particle. It is possible that not all saRNA is encapsulated inside the membrane; some may be attached to the surface, and this saRNA interaction is worth considering. The reason for the decrease in encapsulation efficiency with increasing polymer density may be due to the presence of 40 wt% cholesterol, which increases the hydrophobicity on the lipid membrane and makes the hydrophobic interaction of PP75 with the particles mainly on the surface, rather than by translocation through the lipid membrane. 13 This increased charge density at the surface may collide with the highly negatively charged saRNA via electrostatic repulsion on the surface of the particle, preventing some saRNA from binding to the surface.

[0229] Thus, a 1:1 DOTAP / DOPE ratio, 40 wt% cholesterol, and 0.5 × 10 4 It was found that the use of PP75 polymer chains / particles gave a maximum encapsulation efficiency of approximately 90% in PF-LNPs.

[0230] Cytotoxicity of PF-LNPs The Alamar Blue assay was used to investigate the effect of saRNA-encapsulated PF-LNPs on the metabolic activity of HeLa cervical cancer cells. 4 , 1.0×10 4 and 1.3 × 10 4 HeLa cell viability over 48 h when incubated with saRNA-encapsulated PF-LNPs (DOTAP / DOPE=1:1, 40 wt% cholesterol) coated with PP75 on polymer chains / particles, as well as saRNA-encapsulated LNPs with saRNA only and without PP75 coating. Overall, the relative cell viability remained between 66.1±0.3% and 98.2±0.2%, gradually decreasing over time for all samples. The relative cell viability for saRNA remained above 95.8±1.0%.

[0231] As shown in Figure 5B, at 24 hours, the relative cell viability of PF-LNPs without saRNA was generally slightly higher than that of PF-LNPs with saRNA. Furthermore, when HeLa cells were treated with PF-LNPs with PP75 coating densities within the range tested, no significant change in relative cell viability was observed, and the cell viability remained high at over 80%, comparable to that of saRNA alone. This suggests that PF-LNPs had low or negligible cytotoxicity and that surface coating with anionic endosomolytic amphiphilic polymers did not induce obvious cytotoxicity.

[0232] Damage to plasma membrane integrity can be a good indicator of significant damage prior to cell death, which can be determined by measuring the activity of lactate dehydrogenase (LDH), a stable cytoplasmic enzyme, in the extracellular medium. Figure 5C shows the effect of PF-LNPs with and without saRNA on HeLa cell membrane integrity, as determined using an LDH assay. When HeLa cells were incubated with saRNA alone, there was a high relative cell viability of 91.4 ± 4.5%, indicating that it did not cause significant membrane damage. As the polymer coating density increased, the relative cell viability gradually decreased in both cases of PF-LNPs with and without saRNA. Despite this, HeLa cells generally tolerated PF-LNPs well, with the lowest cell viability being 1.3 × 10 with and without saRNA encapsulation, respectively. 4 78.6 ± 5.51% and 71.3 ± 2.2% for PF-LNPs coated with PP75 polymer chains / particles, suggesting that after 24 h of incubation, the polymers coated on the PF-LNP surface could only contribute to limited membrane damage, even at higher polymer coating densities.

[0233] pH-responsive membrane destabilizing activity of PF-LNPs Hemolysis assays were performed on RBC membranes to model endosomal membranes. 7 The ability of PF-LNP to induce endosomal escape was examined.4 and 1.3 × 10 4 We show the pH-responsive cell membrane destabilizing activity of PF-LNPs coated with PP75 polymer chains / particles. It is clear that the relative hemolysis increased significantly with decreasing physiological pH to early endosomal pH (7.0-6.0). As these results clearly show, an effective cytoplasmic delivery system should have low hemolysis at physiological pH and the ability to efficiently destabilize the membranes of endosomes, preferably early endosomes, upon acidification in the endosomal compartment. 9 .

[0234] Furthermore, as shown in Figure 6A, as the polymer coating density increased, the relative hemolysis increased, reaching 1.3 × 10 4 The hemolysis of saRNA-encapsulated PF-LNPs coated with PP75 polymer chains / particles was the highest, reaching 77.9 ± 6.6% at early endosomal pH 6.0. These results were comparable to the hemolysis of PF-LNPs without saRNA, shown in Figure 6B. This suggests that PP75 coated on the PF-LNP surface has the ability to trigger endosomolytic activity at early endosomal pH, making PF-LNPs a suitable candidate for efficient intracellular delivery of macromolecular payloads, including RNA.

[0235] Effect of lipid composition and polymer coating density on in vitro HEK-293 cell transfection with PF-LNPs saRNA encoding fLuc was added at 0.5 × 10 4 , 1.0×10 4 and 1.3 × 10 4 of polymer chains / particles were encapsulated in PP75-coated PF-LNPs. PF-LNPs containing DOTAP / DOPE at weight ratios of 1:1 (Figure 7A), 1:2 (Figure 7B), and 1:4 (Figure 7C) were transfected into human embryonic kidney 293 (HEK-293) cells to determine the cell transfection efficiency.

[0236] Figure 7A shows that the transfection efficiency of all formulations of PF-LNPs containing a 1:1 weight ratio of DOTAP / DOPE and 40 wt% cholesterol was at least 0.5 orders of magnitude higher than that of the commercial gold standard polyethylenimine (PEI). The highest transfection efficiency was 1.0 × 10 4 and 1.3 × 10 4 of polymer chains / particles was achieved by PP75-coated PF-LNPs, which is 1.5 orders of magnitude higher compared to PEI. 8 Overall, using a 1:1 DOTAP / DOPE weight ratio resulted in the highest transfection efficiency compared with DOTAP / DOPE (1:2) and DOTAP / DOPE (1:4) based PF-LNPs.

[0237] Effect of N / P ratio on in vitro HEK-293 cell transfection with PF-LNPs Furthermore, it was of interest to investigate the effect of the N / P ratio of lipid to saRNA on the transfection efficiency of PF-LNPs with different PP75 coating densities. Figure 8 compares N / P ratios of 0.1, 1, and 10. It was found that as the N / P ratio increased, the transfection efficiency increased. The transfection efficiency was highest for the formulation with an N / P ratio of 10, reaching 1.0 × 10 4 and 1.3 × 10 4 The PF-LNPs containing polymer chains / particles had the highest transfection efficiency. Although the difference in transfection efficiency between N / P ratios of 1 and 10 was statistically significant, an N / P ratio of 1 was selected for in vivo studies.

[0238] Example 2 – In vitro transfection of interferon-competent HeLa cells with PF-LNP In addition to inefficient protein expression, the clinical application of RNA systems is limited by their high innate immunogenicity. RNA delivery using conventional cationic or ionizable LNPs with positive surface charges may induce protective immune responses. Therefore, it is important to achieve a good balance between protein expression and innate immune responses. Figure 9 shows the cell transfection titers of PF-LNPs in interferon-competent HeLa cells. As the dose of saRNA increases, the transfection efficiency substantially increases up to about 10 at 100 ng / well. 7 However, at 1000 ng / well, the transfection efficiency was approximately 10 4.5 RLU, which may be due to the induction of protective immune responses at high saRNA doses. It is noteworthy that delivery of the same saRNA dose of 100 ng / well using the same PF-LNP formulation can result in high transfection efficiency in interferon-competent HeLa cells (Figure 9) comparable to HEK-239 cells (Figure 8). These results suggest that PF-LNPs can perform well on both criteria of protein expression and natural immunogenicity. This may be due to the functionalization of the positively charged LNP surface with anionic pH-responsive endosomolytic pseudopeptides that mimic the anionic fusion peptide in the hemagglutinin spike of influenza virus, resulting in a negative surface charge of PF-LNPs (Figure 3C), preventing direct interaction of cationic / ionizable lipids with cells and resulting in high transfection efficiency in interferon-competent cells.

[0239] These results also demonstrated efficient delivery to a variety of cell types, including cancer cells, indicating the versatility of PF-LNPs for vaccine and gene therapy applications and other therapeutics.

[0240] The inventors noted that overall, PF-LNPs have great potential to perform well in in vivo studies, given that the transfection efficiency is much higher than the commercially available gold standard for intracellular RNA delivery.

[0241] Example 3 – Elucidation of the endocytic mechanism of PF-LNP It is important to design nanocarriers that can release endocytosed biological molecules into the cytoplasm by endosomal escape before they are transported to lysosomes for degradation (Figure 1). We investigated the endocytic mechanism of intracellular delivery of PF-LNPs by using pathway inhibitors at the time of delivery to cells. Six different pathway inhibitors were used, each of which inhibits a specific cellular trafficking pathway. The cellular uptake of PF-LNPs encapsulating enhanced green fluorescent protein-encoding saRNA (EGFP-saRNA) was visualized in confocal images (Figure 10A) and quantified by flow cytometry (Figure 10B). As expected, strong green fluorescence was observed in HEK-293 cells treated only with EGFP-saRNA-encapsulated PF-LNPs, further supporting efficient protein expression in the cells. It is evident that when methyl-β-cyclodextrin (MβCD) was used in combination with EGFP-saRNA-encapsulated PF-LNPs, the green fluorescence intensity was reduced by approximately 80%, and EGFP expression in the cells was the lowest. This means that cellular uptake of PF-LNPs was extremely low as a result of treatment of cells with the inhibitor MβCD, suggesting that lipid raft-mediated endocytosis is the major cellular uptake pathway of PF-LNPs.

[0242] This finding indicates the mechanistic pathway that PF-LNPs take to enter cells. Knowing this allows us to better understand how the delivery system works in order to determine which payloads are most suitable for delivery using PF-LNPs. It also allows us to predict the behavior of PF-LNPs under certain conditions.

[0243] The results of this study indicate that any payload that needs to enter cells via the clathrin-dependent endocytosis pathway, the most common intracellular delivery route, can be successfully entered with our delivery system.

[0244] Example 4 - In vivo studies showing efficient protein expression and excellent immunogenicity effects in mouse models, as well as improved lymph node drainage thanks to the favorable surface chemistry of PF-LNPs High transfection efficiencies achieved in vitro in HEK-293 (Figures 7 and 8) and interferon-competent HeLa cells (Figure 9), and the fact that in vitro results do not necessarily translate to in vivo 16 Considering this fact, it is important to determine whether the PF-LNPs developed in Example 1 are capable of delivering saRNA in vivo.

[0245] Figure 11 shows that the polymer coating density on PF-LNPs played an important role in resulting in higher luciferase expression in mice. As the PP75 coating density increased, luciferase expression increased significantly and was relatively more dispersed. These images further highlight that PF-LNPs play a major role in more efficient intracellular delivery of nucleic acids in vivo.

[0246] Efficient in vivo luciferase expression led to in vivo immunogenicity testing of various PF-LNP formulations, demonstrating the potential of this delivery system for use in RNA vaccines. Female BALB / c mice were inoculated with 1.0 × 10 4 and 1.3 × 10 4 Hemagglutinin influenza virus-encoded saRNA (HA-saRNA) was injected into PF-LNPs containing PP75 polymer chains / particles. Naive, HA-saRNA complexed with jetPEI, and HA-saRNA-encapsulated LNPs without PP75 coating were also tested as controls. A 0.1 μg dose was additionally used, 1.3 × 10 4Each formulation was loaded with 1 μg of HA-saRNA, except for the PF-LNP formulation coated with PP75 polymer chains / particles. Mice received a first injection, followed by a second dose 4 weeks later. HA IgG antibody titers were quantified at week 4, prior to administration of the second dose, and at week 6, 2 weeks after the second dose (FIG. 12B). Survival rates (FIG. 12A) and body weights (FIG. 12C) were also recorded at the end of each week of the study.

[0247] As shown in Figure 12B, mice treated with naïve HA-saRNA showed a marked increase in the amount of saRNA, likely due to degradation of saRNA by RNAase. 17 None of the mice survived past day 5 after influenza challenge was introduced, resulting in the sudden weight loss observed in Figure 12C due to PP75 coating. Mice treated with HA-saRNA encapsulated LNPs without PP75 coating only had 40% survival by day 6, and sudden weight loss was observed by day 5. This was reflected in the antibody titers (Figure 12A), indicating relatively low antibody expression. The negative surface charge of PF-LNPs (Figure 3B) could explain this; the negative charge allows the delivery system to drain more easily into lymph nodes, resulting in a higher immune response. 11 .

[0248] Without PP75 coating, the overall charge of PF-LNP is positive (Figure 3B), resulting in reduced antibody expression. Interestingly, the remaining 40% of mice experienced weight gain after day 5, suggesting that a second dose at week 4 may have a therapeutic effect on the remaining mice. All other groups had 100% survival and maintained healthy weight changes. Looking more closely at antibody titers (Figure 12A), PF-LNPs produced high antibody levels by week 4 comparable to the gold standard, jetPEI (approximately 10 4 ng / mL). 4The group given a low dose of 0.1 μg HA-saRNA formulated in PF-LNPs coated with the polymer chain / particle PP75 also yielded promising results. Antibody expression was comparable to jetPEI complexed with 1 μg HA-saRNA, but a slightly lower body weight percentage was observed. This suggests that PF-LNPs have the ability to elicit a similar immune response with low doses of HA-saRNA, and overall, the anionic, viral-peptidomimetic, endosomolytic polymer coated on the PF-LNP surface plays a key role in making this happen, which is a major advantage in the field of RNA delivery.

[0249] The next logical step was to confirm the hypothesis that surface functionalization of LNPs with anionic, biomimetic, amphiphilic polymers would enhance RNA egress into lymph nodes, resulting in higher protein expression. 4 polymer chain / particle (Figure 13B) and 1.3 × 10 4 We investigated lymph node drainage in a mouse model by comparing EGFP-saRNA-encapsulated PF-LNPs coated with Cy5-PP75 of polymer chains / particles (Figure 13C). The pink areas in the wide-field microscopy images represent the adipose tissue of the lymph node, and the blue areas represent the nuclei. Importantly, the fluorescence images show substantially stronger green fluorescence for EGFP-saRNA-encapsulated PF-LNPs compared to EGFP-saRNA alone, and a significant increase in green fluorescence with increasing PP75 coating density. This suggests that surface functionalization of nanoparticles with anionic amphiphilic polymers enhances drainage of PF-LNPs to lymph nodes, which is highly advantageous for vaccine applications where triggering of protein expression is essential.

[0250] Example 5 – Co-delivery of RNA and small molecules using PF-LNPs Co-delivery of saRNA and ruxolitinib into MRC-5 cells 1.3×10 4The co-delivery of saRNA with the targeted therapeutic drug ruxolitinib, a Janus-associated kinase (JAK) inhibitor with selectivity for subtypes JAK1 and JAK2, using PF-LNPs coated with polymer chains / particles PP75 was investigated to investigate the effect of the introduction of small molecule drugs on the encapsulation efficiency of macromolecules such as nucleic acids and on the cell transfection efficiency. Figure 14 shows that the saRNA encapsulation efficiency increased from 69.0 ± 3.91% to 73.5 ± 11.6% as the ruxolitinib concentration increased from zero to 0.02 μg / mL. However, further increase in ruxolitinib concentration resulted in a decrease in the saRNA encapsulation efficiency, possibly due to the high amount of small molecule drug filling the voids along with the saRNA, which may limit the space available for encapsulation. To the best of our knowledge, the co-delivery of small molecule drugs and saRNA has not yet been achieved due to stability issues as a result of the extremely negative charge of saRNA. This further supports the stability and robustness of the versatile PF-LNPs.

[0251] Using the fLuc assay, the cell transfection efficiency into human fetal lung fibroblast MRC-5 cells was investigated. As shown in Figure 15, as the concentration of ruxolitinib increased, the transfection efficiency of saRNA-encapsulated PF-LNPs also increased. DOTAP / DOPE (1:1), 40 wt% cholesterol, 1.3 x 10 4 PF-LNPs containing PP75 polymer chains / particles and 1 μg / mL ruxolitinib yielded a maximum transfection efficiency approximately two orders of magnitude higher than that of commercial PEI, indicating that the introduction of ruxolitinib into the system can enhance the transfection efficiency of saRNA significantly higher than that of the gold standard PEI without compromising the stability of the system.

[0252] Co-delivery of saRNA and trehalose into HEK-293 cells Co-delivery of trehalose, a protective agent capable of stabilizing biomolecules during freezing and drying, was investigated to evaluate the feasibility of stable storage of RNA-encapsulated PF-LNPs, both lyophilized and in aqueous solutions, at room and tropical temperatures without compromising the integrity of the lipid structure or functionality of the payload.

[0253] FIG. 16 shows that trehalose coexists both inside and outside of PF-LNP. 4 Characterization of PP75-coated saRNA-encapsulated PF-LNP formulations in both aqueous and lyophilized polymer chains / particles and successful HEK-293 cell transfection are demonstrated. Figure 16A shows that by using trehalose concentrations of 63 mg / mL or higher, particle size remained below 200 nm and PDI values ​​were below 0.6 for all PF-LNP formulations. Figure 16B shows that as higher concentrations of trehalose were used, the zeta potential became more negative, with the lowest at -57.3 ± 3.6 mV for lyophilized PF-LNPs containing 500 mg / mL trehalose. Furthermore, the lyophilized formulations had a more negative zeta potential compared to the respective formulations in aqueous solution. HEK-293 cell transfection shown in Figure 16C demonstrated the synergistic effect of trehalose on cell transfection efficiency. As the trehalose concentration increased, the transfection efficiency increased from 10 to 100 at 250 and 500 mg / mL trehalose. 8 The RLU also reached 1.04 mg / mL, suggesting that the coexistence of trehalose both inside and outside the PF-LNPs could maintain the high efficacy of saRNA in aqueous solution and even after lyophilization.

[0254] However, there is a threshold for how much trehalose can be included in a PF-LNP formulation. Trehalose concentrations as high as 500 mg / mL may have some cytotoxic effects for such a delivery system, as demonstrated in FIG. 18, which compares the viability of HEK-293 cells when treated with PF-LNP formulations in aqueous solution (FIG. 17A) and lyophilized (FIG. 17B) containing various concentrations of trehalose. The lyophilized formulation containing 500 mg / mL trehalose resulted in the lowest relative cell viability at 53.3±8.0% after 48 hours of incubation (FIG. 17B). Therefore, a concentration of 250 mg / mL was used for long-term storage studies due to the high negative surface charge and high transfection efficiency generated by its use.

[0255] Example 6 – Co-encapsulation of stabilizing molecules into both aqueous and lyophilized PF-LNP formulations for long-term stable storage of RNA at ambient temperature After optimizing PF-LNPs with trehalose co-encapsulation, long-term storage studies were performed to measure particle size, surface charge, HEK-293 cell viability and HE-293 cell transfection of PF-LNPs co-encapsulated with saRNA and trehalose over time at various temperatures. Four storage temperatures were used: -20 °C, 4 °C, 20 °C and 40 °C to mimic freezer, refrigerator, room and tropical conditions. Figure 18 demonstrates the interaction of trehalose with RNA-encapsulated PF-LNPs both in aqueous solution and lyophilized. Trehalose is present both inside and outside of PF-LNPs, providing protection from both sides and ensuring the desired physical stability (e.g., prevention of particle aggregation and payload leakage) and chemical stability (e.g., protection of biomolecules such as RNA) of the nanoparticles during fabrication and storage, thus maintaining and extending the functionality of saRNA.

[0256] FIG. 19 shows that 250 mg / mL trehalose coexists on both the inside and outside of PF-LNP (PF-LNP / tre). 4Characterization of saRNA-encapsulated PF-LNP coated with PP75 polymer chains / particles in aqueous solution and lyophilized formulations is shown. When fresh, particle size remained below 200 nm and PDI was below 0.5. This was true for both PF-LNP / tre and uncoated LNP (LNP / tre). After 52 weeks of storage at -20 °C, both PF-LNP / tre and LNP-tre maintained similar hydrodynamic size compared to the fresh formulation, but their PDI values ​​increased at week 16, with a more significant change for LNP / tre, which then further increased to about 1.0 at week 52. Over 52 weeks at 4 °C, PF-LNP / tre remained below 200 nm in size and PDI below about 0.8. However, LNP / tre increased in size to 200-300 nm and PDI to 1 after extended storage, suggesting that the particles may have aggregated. Over 52 weeks, hydrodynamic size and PDI increased for both PF-LNP / tre and LNP / tre at 20° C., and more significantly at 40° C. Overall, PF-LNP / tre shows greater stability of hydrodynamic size and PDI than LNP / tre over 52 weeks.

[0257] FIG. 20 shows the zeta potential of PF-LNP / tre and LNP / tre in aqueous solution and lyophilized over 52 weeks. Fresh PF-LNP / tre and LNP / tre in solution had zeta potentials of -57.8±1.5mV and +10.4±4.5mV, respectively. The zeta potentials of freshly lyophilized PF-LNP / tre and LNP / tre were -48.3±1.8mV and +18.8±3.8mV, respectively. The zeta potentials at all temperatures, -20°C, 4°C, 20°C, and 40°C, remained consistent throughout 52 weeks of storage for both PF-LNP / tre in aqueous solution and lyophilized, with very little variability compared to the fresh formulation. However, the zeta potential of LNP / tre changed from positive to negative over time at all temperatures. This is most likely due to leakage of the highly negatively charged saRNA over time. This suggests that PF-LNPs exhibited enhanced stability compared to LNPs due to their surface functionalization with anionic, viral peptidomimetic, and amphiphilic polymers.

[0258] FIG. 21 shows the HEK-293 cell transfection efficiency of PF-LNP / tre and LNP / tre in aqueous solution and lyophilized over 52 weeks of storage. Fresh PF-LNP / tre and LNP / tre in solution and lyophilized were approximately 10 7 RLU and approximately 10 6Transfection efficiency in RLU was shown. The transfection efficiency of lyophilized PF-LNP / tre after 52 weeks of storage at all temperatures, -20°C, 4°C, 20°C and 40°C respectively, remained consistent at high levels, generally an order of magnitude higher than LNP / tre, throughout the 52-week period. This validated that polymer functionalization and the co-presence of trehalose both inside and outside the nanoparticles can successfully preserve the functionality of saRNA. RNA molecules are very fragile and can easily degrade in exposed environments, requiring highly challenging ultracold or cold chain storage and distribution. For example, the world's first approved COVID-19 vaccine, the Pfizer / BioNTech mRNA vaccine, suffers from a major hurdle requiring storage at -70°C, and at refrigerated temperatures of 2-8°C, it can only be stable for 5 days (Pfizer.com, November 20, 2020). Similarly, the approved Moderna mRNA vaccine against COVID-19 requires storage at -20°C. The excellent thermostability of RNA and high transfection efficiency over a period of one year at room temperature (20°C) and tropical temperatures (40°C) for the PF-LNP formulation demonstrated by the inventors represents a significant technological breakthrough in the manufacturing, storage and distribution of RNA vaccines and biopharmaceuticals, with enormous commercial potential and socio-economic impact.

[0259] As also shown in Figure 21, PF-LNP / tre in aqueous solution during 52 weeks of storage at -20°C, 4°C, 20°C, and 40°C retained good transfection efficiency, although it was approximately one order of magnitude lower compared to lyophilized PF-LNP / tre. At 52 weeks, the transfection efficiency of PF-LNP / tre in aqueous solution was 10 4 RLU > 10 for storage at 40°C 3The RLU remained above 100%. This is an important finding considering that storing RNA in aqueous solution is a major challenge since RNA molecules can be easily degraded by hydrolysis. The favorable thermal stability of RNA vaccines and biopharmaceuticals in aqueous solution at ambient temperature through formulation into PF-LNPs provides another attractive strategy, an alternative to lyophilized formulations, for stable RNA storage that does not require ultracold or cold chains. In addition, it is worth pointing out that (i) although an N / P ratio of 1 was used in this preliminary storage work, using a higher N / P ratio would improve the transfection efficiency (as shown in Figure 8); and (ii) PF-LNP composition and formulation could be further optimized. We believe that the thermal stability of RNA formulated into PF-LNPs after long-term storage at ambient temperature could be further enhanced after optimization.

[0260] Figure 22 shows that the relative viability of HEK-293, as determined using the Alamar Blue assay, remained above about 70% after 48 hours of treatment with all formulations of PF-LNP, both in aqueous solution and lyophilized, over a 52-week storage period at all temperatures, -20°C, 4°C, 20°C, and 40°C, respectively. These HEK-293 cell viabilities of PF-LNP / tre and LNP / tre were comparable to the negative control saRNA / tre, a mixture of saRNA and trehalose, further confirming that the PF-LNP formulations have negligible or low cytotoxicity.

[0261] Example 7 – Preparation and characterization of PEGylated PF-LNPs, showing high biocompatibility and low cytotoxicity, as well as high in vitro transfection efficiency via efficient intracellular RNA delivery We synthesized PEGylated polymer-functionalized lipid nanoparticles (PEGylated PF-LNPs) as described in the Materials and Methods section below. The PEGylated PF-LNPs were coated with PP75, a biocompatible, pH-responsive, endosomolytic pseudopeptide polymer that mimics the anionic fusogenic peptide in the hemagglutinin spike of influenza virus.

[0262] Physiochemical characterization of PEGylated PF-LNPs Figure 23 shows the effect of polymer density on the hydrodynamic diameter, PDI and zeta potential of PEGylated PF-LNPs in aqueous solution and lyophilized form. In aqueous solution, the mean particle size shown in Figure 23A was found to be similar at 112.0±69.0 nm for PF-LNPs coated with 0.25 mg / mL, 0.5 mg / mL and 1 mg / mL PP75. The PDI was also similar at about 0.2, suggesting that the PEGylated PF-LNPs were monodisperse. In comparison, the lyophilized formulation showed a slightly higher mean hydrodynamic diameter at 128±23.0 nm and a PDI of about 0.4. However, these monodisperse particles were still below 200 nm for effective intracellular delivery. The charge of the particles, as shown by the zeta potential in FIG. 23B, varied from +15.9±0.5 mV for PEGylated LNPs without PP75 coating to -55.4±0.3 mV for PEGylated PF-LNPs containing 1 mg / mL PP75. Both the aqueous and lyophilized formulations followed the same trend. The switch between positive and negative charges occurred between 0.25 mg / mL and 0.5 mg / mL. As previously mentioned, negative charges are more efficient at draining to lymph nodes (as demonstrated in Example 4) and induce high levels of antibody production, so 11 , which is beneficial for vaccine applications, which is one of the major advantages of these delivery systems.

[0263] In situ loading of calcein, FITC-dextran and saRNA into PEGylated PF-LNPs In situ loading of model payloads calcein (Mw 622.55 Da) and FITC-dextran (Mw 150 kDa) into PF-LNPs coated with 1 mg / mL PP75 was investigated to demonstrate the ability of PEGylated PF-LNPs to encapsulate a wide range of payloads. Figure 24A shows that the encapsulation efficiency of calcein and FITC-dextran into PEGylated LNPs was 80.9 ± 1.8% and 76.9 ± 2.4%, respectively. Figure 24B shows that the encapsulation efficiency of saRNA into PEGylated PF-LNPs coated with 1 mg / mL PP75 was 84.91 ± 2.32%, as determined by RiboGreen™ assay. This is as expected for passively loaded payloads.

[0264] Example 8 – Co-encapsulation of stabilizing molecules into both aqueous and lyophilized PEGylated PF-LNP formulations for long-term stable storage of RNA at ambient temperature After optimizing the PEGylated PF-LNPs with trehalose co-encapsulation, long-term storage studies were performed to measure particle size, surface charge, HEK293 cell viability and HEK-293 cell transfection of PEGylated PF-LNPs co-encapsulated with saRNA and trehalose over time at various temperatures. Four storage temperatures were used: -20 °C, 4 °C, 20 °C and 40 °C to mimic freezer, refrigerator, room and tropical conditions. Trehalose is present both inside and outside the PF-LNPs, providing protection from both sides and ensuring the desired physical stability (e.g., prevention of particle aggregation and payload leakage) and chemical stability (e.g., protection of biomolecules such as RNA) of the nanoparticles during fabrication and storage, thus maintaining and extending the functionality of saRNA.

[0265] Figure 25 shows the characterization of formulations in aqueous solution [A] and lyophilized [B] of saRNA-encapsulated PEGylated PF-LNPs coated with 1 mg / mL PP75 with 250 mg / mL trehalose coexisting both inside and outside the PEGylated PF-LNPs (PEGylated PF-LNP / tre). When fresh, particle size remained below 150 nm and PDI was below 0.4. This was true for both PEGylated PF-LNP / tre and uncoated PEGylated LNPs (PEGylated LNP / tre). After 9 weeks of storage at -20°C, 4°C, 20°C and 40°C, both PEGylated PF-LNP / tre and PEGylated LNP / tre maintained similar hydrodynamic size and PDI compared to the fresh formulation. Overall, both PEGylated PF-LNP / tre and PEGylated LNP / tre showed hydrodynamic size and PDI stability over 9 weeks in aqueous solution and lyophilized form.

[0266] FIG. 26 shows the zeta potential of PEGylated PF-LNP / tre and PEGylated LNP / tre in aqueous solution [A] and lyophilized [B] over a 9-week period. Fresh PF-LNP / tre and LNP / tre in solution had zeta potentials of -55.4±0.3mV and +15.9±0.5mV, respectively. The zeta potentials of freshly lyophilized PEGylated PF-LNP / tre and PEGylated LNP / tre were -52.1±1.6mV and +10.5±5.2mV, respectively. The zeta potentials at all temperatures, -20°C, 4°C, 20°C, and 40°C, remained consistent throughout 9 weeks of storage for both PEGylated PF-LNP / tre and PEGylated LNP / tre in aqueous solution and lyophilized form, with much less variability compared to the fresh formulations.

[0267] Figure 27 shows the HEK-293 cell transfection efficiency of PEGylated PF-LNP / tre and PEGylated LNP / tre in aqueous solution and lyophilized over 9 weeks of storage. Fresh PEGylated PF-LNP / tre and PEGylated LNP / tre in solution and lyophilized showed approximately 10% transfection efficiency, respectively. 7 RLU and approximately 10 6Transfection efficiencies in RLU were shown. The transfection efficiencies of lyophilized PEGylated PF-LNP / tre and PEGylated LNP / tre after 9 weeks of storage at all temperatures, -20 °C, 4 °C, 20 °C and 40 °C, respectively, remained consistent throughout and showed less variability compared to the fresh formulations, while PEGylated LNP / tre transfection efficiency generally remained an order of magnitude lower than PEGylated PF-LNP / tre throughout the 9-week period. This validated that the co-presence of trehalose both inside and outside the nanoparticles for both PEGylated PF-LNPs with polymer functionalization and PEGylated LNPs without polymer can successfully maintain the functionality of saRNA. The excellent thermal stability of RNA and high transfection efficiency at room temperature (20 °C) and tropical temperatures (40 °C) demonstrated by the inventors, especially for the PEGylated PF-LNP formulation, represents another important technological breakthrough in the manufacturing, storage and distribution of RNA vaccines and biopharmaceuticals, with enormous commercial potential and socio-economic impact.

[0268] As also shown in Figure 27, the HEK-293 transfection efficiency of PEGylated PF-LNP / tre and PEGylated LNP / tre in aqueous solution after 9 weeks of storage at -20°C, 4°C, 20°C and 40°C remained consistent throughout and showed less variability compared to the fresh formulations. PEGylated LNP / tre transfection efficiency was generally up to an order of magnitude lower than PEGylated PF-LNP / tre throughout 9 weeks of storage in aqueous solution at all these temperatures tested. These are important findings considering that storing RNA in aqueous solution is a major challenge as RNA molecules can be easily degraded by hydrolysis. In addition, it is worth pointing out that (i) an N / P ratio of 1 was used in this preliminary storage work, but using a higher N / P ratio would improve the transfection efficiency (as shown in Figure 8 for PF-LNP); and (ii) PEGylated PF-LNP composition and formulation could be further optimized. We believe that the thermal stability of RNA formulated in PF-LNP after long-term storage at ambient temperature could be further enhanced after optimization.

[0269] Figure 28 shows that the relative viability of HEK293, as determined using the Alamar Blue assay, remained greater than about 90% after 48 hours of treatment with all formulations of PEGylated PF-LNP and PEGylated LNP, both in aqueous solution and lyophilized, throughout the 9-week storage period at all temperatures, -20°C, 4°C, 20°C, and 40°C, respectively. These HEK293 cell viabilities of PEGylated PF-LNP and PEGylated LNP were comparable to the negative control saRNA+tre, a mixture of saRNA and trehalose, further confirming that the PF-LNP formulations have negligible or low cytotoxicity.

[0270] Example 9 – Preparation and characterization of MC3 PF-LNPs, showing high biocompatibility and low cytotoxicity, as well as high in vitro transfection efficiency via efficient intracellular RNA delivery We synthesized polymer-functionalized lipid nanoparticles based on D-Lin-MC3-DMA ionizable lipids (MC3 PF-LNPs) as described in the Materials and Methods section below. MC3 PF-LNPs were coated with three different biocompatible, pH-responsive, endosomolytic pseudopeptide polymers, PP75, PLP-NDA, and PLP-ADA, which mimic the anionic fusion peptide in the hemagglutinin spike of influenza virus.

[0271] PP75 is a pseudopeptide prepared by grafting the hydrophobic amino acid L-phenylalanine onto pendant carboxylic acids on the backbone of poly(L-lysine isophthalamide) (PLP), a linear metabolite-derived polyamide, with a stoichiometric degree of substitution of 75%. The biomimetic anionic amphiphilic polymer contains hydrophobic pendant groups and ionizable carboxylic acid groups found in the fusion peptide of influenza virus.

[0272] PLP-NDA is a pH-responsive comb-like polymer that exhibits superior membrane anchoring and disruption capabilities compared to PLP. The PLP-NDA polymer used in this study is synthesized by grafting hydrophobic decylamine (NDA), which acts as a membrane anchor, onto the pendant carboxylic acid groups of PLP at a grafting rate of approximately 18%. This polymer has been shown to exhibit superior membrane disruption capabilities at endosomal pH and, like PP75, does not undergo membrane disruption at physiological pH (pH 7.4).

[0273] [ka]

[0274] PLP-ADA is a pH-responsive comb-like polymer with 12-aminododecanoic acid (ADA) grafted as a hydrophobic side chain onto the PLP backbone for optimal intracellular delivery. The PLP-ADA polymer used in this study contains a 60% grafting rate with ADA.

[0275] [ka]

[0276] Physiochemical characterization of MC3 PF-LNPs FIG. 29 shows the effect of PP75, PLP-NDA, and PLP-ADA polymer density on the hydrodynamic diameter, PDI, and zeta potential of MC3 PF-LNP. The mean particle size shown in FIG. 29A was found to be similar at about 150 nm for MC3 PF-LNP coated with 0.5 mg / mL and 1 mg / mL PP75. The PDI of the PP75-coated formulation was also similar at about 0.3, suggesting that the MC3 PF-LNP was monodisperse. The uncoated MC3 LNP had a PDI of 0.53±0.2, so was more polydisperse than the polymer-functionalized formulation. Similarly, the mean particle size shown in FIG. 29B was found to be similar at about 150 nm for MC3 PF-LNP coated with 0.5 mg / mL and 1 mg / mL PLP-NDA. The PDI of the PLP-NDA-coated formulation was also similar at about 0.4, suggesting that the MC3 PF-LNP was monodisperse. In comparison, the mean particle size shown in Figure 29C was about 150 nm for MC3 PF-LNPs coated with 0.5 mg / mL PLP-ADA, similar to the other two polymer-coated PF-LNPs, and increased to about 200 nm at 1 mg / mL. The PDI of the PLP-ADA-coated formulations was about 0.5 and about 0.3 for 0.5 mg / mL and 1 mg / mL PLP-ADA, respectively. This suggests that the PLP-ADA-coated MC3 PF-LNPs were monodisperse. Also, these monodisperse particles were all less than 200 nm, making the particles suitable for effective intracellular delivery. The charge of the particles, as shown by the zeta potential in Figures 29A, B and C, varied from -1.6 ± 0.5 mV for MC3 LNP without polymer coating, to -8.8 ± 0.6 mV for MC3 PF-LNP with 1 mg / mL PP75, -22.3 ± 0.2 mV for MC3 PF-LNP with 1 mg / mL PLP-NDA and -18.9 ± 0.9 mV for MC3 PF-LNP with 1 mg / mL PLP-ADA. All formulations followed the same trend; as the polymer concentration increased, the zeta potential decreased. As previously mentioned, negative charges lead to high antibody production. 11, which is beneficial for vaccine applications due to enhanced drainage to lymph nodes (demonstrated in Example 4). As shown in Figure 30, the hydrodynamic size and zeta potential of MC3 PF-LNPs were not significantly affected when saRNA was encapsulated, regardless of the type of polymer coating.

[0277] In situ loading of calcein, FITC-dextran and saRNA into MC3 PF-LNPs In situ loading of model payloads calcein (Mw 622.55 Da) and FITC-dextran (Mw 150 kDa) into MC3 LNPs was investigated to demonstrate the ability of MC3 LNPs to encapsulate a wide range of payloads. Figure 31A shows that the encapsulation efficiency of calcein and FITC-dextran was 65.8 ± 3.5% and 60.2 ± 4.8%, respectively. Figure 31B shows that the encapsulation efficiency of saRNA into MC3 PF-LNPs was 66.82 ± 1.54%, as determined by RiboGreen™ assay. This is as expected for passively loaded payloads.

[0278] Figure 32 shows the HEK-293 cell transfection efficiency of MC3 PF-LNPs and MC3 LNPs coated with PP75, PLP-NDA or PLP-ADA. As shown, polymer functionalization plays a key role in enhancing the transfection efficiency of saRNA; as the polymer concentration increased, the transfection efficiency increased by at least one order of magnitude. PP75 coating performed best compared to other polymers, with a transfection efficiency of approximately 10 at 1 mg / mL of PP75. 7.5 It was RLU.

[0279] Figure 33 shows that the relative viability of HEK-293 cells, as determined using the Alamar Blue assay, remained above 80% after 48 hours of treatment with all formulations of MC3 PF-LNP and MC3 LNP, confirming that the PF-LNP formulations have negligible or low cytotoxicity.

[0280] Figure 34 shows the pH-dependent size and surface charge changes of MC3 LNPs. As the pH increased, the hydrodynamic size of MC3 LNPs decreased, with a lowest of 88.13 ± 6.9 nm at pH 7.4, as shown in Figure 34A. Despite the higher hydrodynamic size at lower pH, the size remained below 200 nm, making it suitable for cellular uptake. The PDI of the formulations was variable, ranging from PDI 0.2 to PDI 1.0, suggesting polydispersity, but polymer functionalization would impart stability to the nanoparticles. Figure 34B showed that as the pH increased, the zeta potential of MC3 LNPs gradually decreased. This is expected, as this is the typical behavior of ionizable lipids.

[0281] Example 10 – Co-encapsulation of stabilizing molecules into both aqueous and lyophilized MC3 PF-LNP formulations for long-term stable storage of RNA at ambient temperature After optimizing MC3 PF-LNPs with trehalose co-encapsulation, long-term storage studies were performed to measure particle size, surface charge, HEK-293 cell viability and HEK-293 cell transfection of MC3 PF-LNPs co-encapsulated with saRNA and trehalose over time at various temperatures. Three storage temperatures, -20 °C, 4 °C and 20 °C, were used to mimic freezer, refrigerator and ambient conditions. Trehalose is present both inside and outside the PF-LNPs, providing protection from both sides and ensuring the desired physical stability (e.g., prevention of particle aggregation and payload leakage) and chemical stability (e.g., protection of biomolecules such as RNA) of the nanoparticles during fabrication and storage, thus maintaining and extending the functionality of saRNA.

[0282] Figure 35 shows the characterization of aqueous and lyophilized formulations of saRNA-encapsulated MC3 PF-LNP coated with 1 mg / mL PP75, PLP-NDA or PLP-ADA with 250 mg / mL trehalose coexisting both inside and outside the MC3 PF-LNP (MC3 PF-LNP / tre). When fresh, particle size remained below 150 nm and PDI was below about 0.4 for all three polymer-coated MC3 PF-LNPs. This was true for both fresh MC3 PF-LNP / tre and fresh uncoated MC3 LNPs (PEGylated LNP / tre) at week 0. After 11 weeks of storage at -20°C, 4°C and 20°C, MC3 PF-LNP / tre maintained similar hydrodynamic size and PDI compared to the fresh formulations. Uncoated MC3 PF-LNP / tre was the most unstable at all temperatures tested, with a hydrodynamic size of approximately 250 nm and a PDI of 0.6. Lyophilized forms of MC3 PF-LNP / tre and MC3 LNP / tre followed similar trends to the aqueous formulations at various temperatures. Overall, MC3 PF-LNP / tre showed stability of hydrodynamic size and PDI over 11 weeks in both aqueous and lyophilized forms.

[0283] Figure 36 shows the zeta electrons of MC3 PF-LNP / tre and MC3 LNP / tre coated with 1 mg / mL PP75, PLP-NDA or PLP-ADA in aqueous solution and lyophilized form over 11 weeks. Fresh MC3 PF-LNP / tre and MC3 LNP / tre with PP75, PLP-NDA or PLP-ADA in solution had zeta potentials of -14.6 ± 0.4 mV, -25.5 ± 0.7 mV, -24.7 ± 0.6 mV and -7.5 ± 0.8 mV, respectively. The zeta potentials of freshly lyophilized MC3 PF-LNP / tre and MC3 LNP / tre with PP75, PLP-NDA or PLP-ADA were -15.2 ± 0.3 mV, -23.5 ± 0.2 mV, -28.0 ± 0.3 mV and -8.4 ± 0.7 mV, respectively. The zeta potential at all temperatures, −20° C., 4° C., and 20° C., remained consistent throughout 11 weeks of storage for both MC3 PF-LNP / tre and MC3 LNP / tre in aqueous and lyophilized form, with much less variability compared to the fresh formulations.

[0284] Figure 37 shows the HEK-293 cell transfection efficiency of MC3 PF-LNP / tre and MC3 LNP / tre containing 1 mg / mL PP75, PLP-NDA or PLP-ADA in aqueous solution and lyophilized form over 11 weeks of storage. Fresh MC3 PF-LNP / tre and MC3 LNP / tre in solution and lyophilized form, respectively, showed approximately 10 7.5 RLU and approx. 10 6Transfection efficiencies in RLU were shown. The transfection efficiencies of lyophilized MC3 PF-LNP / tre and MC3 LNP / tre after 11 weeks of storage at all temperatures, -20 °C, 4 °C, and 20 °C, respectively, remained consistent throughout and showed less variability compared to the fresh formulations, although MC3 LNP / tre transfection efficiencies generally remained 1-3 orders of magnitude lower than MC3 PF-LNP / tre throughout the 11-week period (Figure 37B). This validated that the co-presence of trehalose both inside and outside the nanoparticles for both MC3 PF-LNP with polymer functionalization and MC3 LNP without polymer can successfully maintain the functionality of saRNA. The excellent thermal stability of RNA at room temperature (20 °C) and high transfection efficiency, especially for the MC3 PF-LNP formulation, that we demonstrated represents another important technological breakthrough in the manufacturing, storage, and distribution of RNA vaccines and biopharmaceuticals, with enormous commercial potential and socio-economic impact.

[0285] As also shown in Figure 37A, HEK-293 transfection efficiencies of MC3 PF-LNP / tre and MC3 LNP / tre in aqueous solution after 11 weeks of storage at -20°C, 4°C, and 20°C remained consistent throughout and showed less variability compared to the fresh formulations. MC3 LNP / tre transfection efficiencies generally remained 1-3 orders of magnitude lower than MC3 PF-LNP / tre throughout 11 weeks of storage in aqueous solution at all these temperatures tested. These are also important findings considering that storing RNA in aqueous solution is a major challenge. In addition, it is worth pointing out that, like previous formulations, (i) an N / P ratio of 1 was used in this preliminary storage work, but using a higher N / P ratio (as shown in Figure 8 for PF-LNP) improves transfection efficiency; and (ii) the MC3 PF-LNP composition and formulation can be further optimized. We believe that the thermal stability of RNA formulated in PF-LNP after long-term storage at ambient temperature may be further enhanced after optimization.

[0286] Figure 38 shows that the relative viability of HEK-293, as determined using the Alamar Blue assay, remained above about 80% after 48 hours of treatment with all formulations of MC3 PF-LNP and MC3 LNP in both aqueous and lyophilized form over an 11-week storage period at all temperatures of -20°C, 4°C, and 20°C, respectively. These HEK-293 cell viabilities of MC3 PF-LNP and MC3 LNP were comparable to the negative control saRNA+tre, a mixture of saRNA and trehalose, further confirming that the PF-LNP formulations have negligible or low cytotoxicity.

[0287] Example 11 – Preparation and characterization of DODAP PF-LNPs, showing high biocompatibility and low cytotoxicity, as well as high in vitro transfection efficiency via efficient intracellular RNA delivery We synthesized polymer-functionalized lipid nanoparticles based on (1,2-dioleoyl-3-dimethylammonium-propane) ionizable lipids (DOTAP PF-LNPs) as described in the Materials and Methods section below. DOTAP PF-LNPs were coated with three different pseudopeptide polymers: PP75, PLP-NDA, and PLP-ADA.

[0288] Physiochemical characterization of DODAP PF-LNPs FIG. 39 shows the effect of PP75, PLP-NDA, and PLP-ADA polymer density on the hydrodynamic diameter, PDI, and zeta potential of DODAP PF-LNP. The mean particle size shown in FIG. 39A was found to be similar at about 150 nm for DODAP PF-LNP coated with 0.5 mg / mL and 1 mg / mL PP75. The PDI of the PP75-coated formulation was also similar at about 0.2-0.4, suggesting that the MC3 PF-LNP was monodisperse. The uncoated DODAP LNP had a PDI of 0.22±0.1, so was monodisperse, similar to the polymer-functionalized formulation. Similarly, the mean particle size shown in FIG. 39B was found to be similar at about 150 nm for DODAP PF-LNP coated with 0.5 mg / mL and 1 mg / mL PLP-NDA. The PDI of the formulations coated with PLP-NDA was also similar at about 0.3, suggesting that the DODAP PF-LNPs were monodisperse. In comparison, the mean particle size shown in FIG. 39C was about 150 nm for DODAP PF-LNPs coated with 0.5 mg / mL and 1 mg / mL PLP-ADA, similar to the other two polymer-coated PF-LNPs. The PDI of the PLP-ADA-coated formulations was about 0.4 for 0.5 mg / mL and 1 mg / mL PLP-ADA, suggesting that the DODAP PF-LNPs coated with PLP-ADA were monodisperse. These monodisperse particles were also all less than 200 nm, making them suitable for effective intracellular delivery. The charge of the particles, as shown by the zeta potential in Figures 39A, B and C, varied from -7.3 ± 0.4 mV for DODAP LNPs without polymer coating to -15.7 ± 0.2 mV for DODAP PF-LNPs with 1 mg / mL PP75, -26.9 ± 1.6 mV for DODAP PF-LNPs with 1 mg / mL PLP-NDA, and -27.9 ± 0.3 mV for DODAP PF-LNPs with 1 mg / mL PLP-ADA. All formulations followed the same trend; as the polymer concentration increased, the zeta potential decreased. As previously mentioned, negative charges lead to high antibody production. 11, which is beneficial for vaccine applications due to enhanced drainage to lymph nodes (demonstrated in Example 4). As shown in Figure 40, the hydrodynamic size and zeta potential of DODAP PF-LNPs were not significantly affected when saRNA was encapsulated, regardless of the type of polymer coating.

[0289] In situ loading of calcein, FITC-dextran and saRNA into DODAP PF-LNPs In situ loading of model payloads calcein (Mw 622.55 Da) and FITC-dextran (Mw 150 kDa) into DODAP LNPs was investigated to demonstrate the ability of DODAP LNPs to encapsulate a wide range of payloads. Figure 41A shows that the encapsulation efficiency of calcein and FITC-dextran was 61.9 ± 0.2% and 58.6 ± 1.7%, respectively. Figure 41B shows that the encapsulation efficiency of saRNA in DODAP PF-LNPs was 62.59 ± 0.25%, as determined by RiboGreen™ assay. This is as expected for passively loaded payloads.

[0290] Figure 42 shows the HEK293 cell transfection efficiency of DODAP PF-LNPs and MC3 LNPs coated with PP75, PLP-NDA or PLP-ADA. As shown, polymer functionalization plays an important role in enhancing the transfection efficiency of saRNA; as the polymer concentration increases, the transfection efficiency increases by at least one order of magnitude. PP75 and PLP-ADA coatings showed the best performance compared to PLP-NDA, with the transfection efficiency at 1 mg / mL of PP75 or PLP-ADA increasing by approximately 10 7.5 It was RLU.

[0291] Figure 43 shows that the relative viability of HEK293 cells, as determined using the Alamar Blue assay, remained above about 80% after 48 hours of treatment with DODAP PF-LNP and all formulations of DODAP LNP, confirming that the PF-LNP formulations have negligible or low cytotoxicity.

[0292] Example 12 –Co-encapsulation of stabilizing molecules into both aqueous and lyophilized DODAP PF-LNP formulations for long-term stable storage of RNA at ambient temperature After optimizing DODAP PF-LNPs with trehalose co-encapsulation, long-term storage studies were performed to measure particle size, surface charge, HEK-293 cell viability and HEK-293 cell transfection of DODAP PF-LNPs co-encapsulated with saRNA and trehalose over time at various temperatures. Three storage temperatures, -20 °C, 4 °C and 20 °C, were used to mimic freezer, refrigerator and ambient conditions. Trehalose is present both inside and outside the PF-LNPs, providing protection from both sides and ensuring the desired physical stability (e.g., prevention of particle aggregation and payload leakage) and chemical stability (e.g., protection of biomolecules such as RNA) of the nanoparticles during fabrication and storage, thus maintaining and extending the functionality of saRNA.

[0293] FIG. 44 shows the characterization of aqueous and lyophilized formulations of saRNA-encapsulated DODAP PF-LNPs coated with 1 mg / mL PP75, PLP-NDA, or PLP-ADA with 250 mg / mL trehalose coexisting both inside and outside the DODAP PF-LNP (DODAP PF-LNP / tre). When fresh, particle size remained below 200 nm with PDIs below about 0.4 for all three polymer-coated DODAP PF-LNPs. The hydrodynamic size of fresh uncoated DODAP LNPs (DODAP LNP / tre) at week 0 was above 200 nm with PDIs of 0.3 and 0.4 for aqueous and lyophilized forms, respectively. After 11 weeks of storage at −20° C., 4° C., and 20° C., DODAP PF-LNP / tre maintained similar hydrodynamic size and PDI compared to the fresh formulations. Uncoated DODAP PF-LNP / tre showed the most instability with a hydrodynamic size of approximately 250 nm and a PDI of 0.6 at all temperatures tested. Lyophilized forms of DODAP PF-LNP / tre and DODAP LNP / tre followed similar trends to the aqueous formulations at various temperatures, except that the PDI of DODAP LNP / tre was less than 0.4 at all temperatures over 8 weeks, suggesting monodisperse particles compared to those in aqueous solutions. Overall, DODAP PF-LNP / tre showed stability of hydrodynamic size and PDI over 11 weeks in aqueous and lyophilized forms.

[0294] Figure 45 shows the zeta potential of DODAP PF-LNP / tre and DODAP LNP / tre coated with 1 mg / mL PP75, PLP-NDA or PLP-ADA in aqueous solution and lyophilized form over 11 weeks. Fresh DODAP PF-LNP / tre and DODAP LNP / tre with PP75, PLP-NDA or PLP-ADA in solution had zeta potentials of -15.2±0.3mV, -266.3±0.8mV, -23.9±0.5mV and -7.7±0.9mV, respectively. The zeta potentials of freshly lyophilized DODAP PF-LNP / tre and DODAP LNP / tre containing PP75, PLP-NDA or PLP-ADA were -16.1 ± 0.2 mV, -24.65 ± 0.4 mV, -29.0 ± 0.2 mV and -8.3 ± 0.8 mV, respectively. The zeta potentials at all temperatures, -20°C, 4°C and 20°C, remained consistent throughout 11 weeks of storage for both DODAP PF-LNP / tre and DODAP LNP / tre in aqueous and lyophilized form, with very little variability compared to the fresh formulations.

[0295] Figure 46 shows the HEK-293 cell transfection efficiency of DODAP PF-LNP / tre and DODAP LNP / tre containing 1 mg / mL PP75, PLP-NDA or PLP-ADA in aqueous solution and lyophilized form over 11 weeks of storage. Fresh DOTAP PF-LNP / tre and DODAP LNP / tre in solution and lyophilized form, respectively, showed approximately 10 7.5 RLU and approximately 10 4Transfection efficiencies in RLU were shown. Although the transfection efficiencies of lyophilized DODAP PF-LNP / tre and DODAP LNP / tre after 11 weeks of storage at all temperatures, -20 °C, 4 °C, and 20 °C, respectively, remained consistent throughout and showed less variability compared to the fresh formulations, DODAP LNP / tre transfection efficiencies generally remained 1-3 orders of magnitude lower than DODAP PF-LNP / tre throughout the 11-week period (Figure 46B). This validated that the co-presence of trehalose both inside and outside the nanoparticles for both DODAP PF-LNPs with polymer functionalization and DODAP LNPs without polymer can successfully maintain the functionality of saRNA. The excellent thermal stability of RNA at room temperature (20 °C) and high transfection efficiency, especially for the DODAP PF-LNP formulation, that we have demonstrated represents another important technological breakthrough in the manufacturing, storage, and distribution of RNA vaccines and biopharmaceuticals, with enormous commercial potential and socio-economic impact.

[0296] As also shown in Figure 46A, HEK-293 transfection efficiencies of DODAP PF-LNP / tre and DODAP LNP / tre in aqueous solution after 11 weeks of storage at -20°C, 4°C, and 20°C remained consistent throughout and showed less variability compared to the fresh formulations. DODAP LNP / tre transfection efficiencies generally remained 1-3 orders of magnitude lower than DODAP PF-LNP / tre throughout 11 weeks of storage in aqueous solution at all these temperatures tested. These are also important findings considering that storing RNA in aqueous solution is a major challenge. In addition, it is worth pointing out that, like previous formulations, (i) an N / P ratio of 1 was used in this preliminary storage work, but using a higher N / P ratio would improve transfection efficiency (as shown in Figure 8 for PF-LNP); and (ii) DODAP PF-LNP composition and formulations could be further optimized. The inventors believe that the thermal stability of RNA formulated in PF-LNPs after long-term storage at ambient temperature may be further enhanced after optimization.

[0297] Figure 47 shows that the relative viability of HEK-293, as determined using the Alamar Blue assay, remained above about 80% after 48 hours of treatment with all formulations of DODAP PF-LNP and DODAP LNP in aqueous and lyophilized form throughout the 11-week storage period at all temperatures, -20°C, 4°C, and 20°C, respectively. These HEK-293 cell viabilities of DODAP PF-LNP and DODAP LNP were comparable to the negative control saRNA+tre, a mixture of saRNA and trehalose, further confirming that the PF-LNP formulations have negligible or low cytotoxicity.

[0298] Overall, it has been demonstrated that surface functionalization with anionic, viral peptidomimetic, endosomolytic polymers PP75, PLP-NDA and PLP-ADA, in combination with co-delivery of trehalose, plays a crucial role in stabilizing RNA-encapsulated PF-LNP formulations composed of cationic and ionizable lipids, both in aqueous solution and lyophilized, for at least 52 weeks at freezer (-20°C), refrigerator (4°C), room (20°C) and tropical (40°C) temperatures, ensuring physical and chemical stability as well as superior transfection efficiency of the RNA delivery nanoformulations.

[0299] conclusion This invention demonstrates the preparation, characterization and application of PF-LNPs for efficient in vitro and in vivo intracellular delivery of nucleic acids, including RNA, as well as stable storage at room and tropical temperatures without the need for ultracold or cold chains. Physiochemical characterization of PF-LNPs, PEGylated PF-LNPs, MC3 PF-LNPs and DODAP PF-LNPs showed average particle sizes below 200 nm with a low zeta potential of -41.7 ± 3.7 mV, making this system ideal for intracellular delivery of RNA vaccines and biopharmaceuticals. In addition, a high saRNA encapsulation efficiency of 87.2 ± 9.8% was achieved, which is ideal for delivering high doses in smaller volumes. Transfection efficiency 1.5 orders of magnitude higher than that of the commercial gold standard, PEI, was achieved. PF-LNPs can maintain a good balance between protein expression and innate responses and show excellent transfection efficiency in interferon-competent cells. We assume the same is true for PEGylated PF-LNP, MC3-PF-LNP and DODAP PF-LNP. Anionic, endosomolytic, non-cytotoxic PF-LNP showed improved lymph node drainage, efficient protein expression and superior immunogenicity in vivo. We assume the same is true for PEGylated PF-LNP, MC3-PF-LNP and DODAP PF-LNP. The PF-LNP platform is extremely versatile with a demonstrated ability to co-deliver small molecule drugs along with macromolecules. The unique structure-property relationship of this technology allowed us to demonstrate that by modifying the lipid composition to include ionizable lipids (MC3 PF-LNP and DODAP PF-LNP) or modifying the polymer coating (with PEGylation or PLP-NDA and PLP-ADA), we can produce LNPs that are more chemically, physically and biologically stable than their original PF-LNP counterparts.The presence of stabilizing molecules such as trehalose both inside and outside the various PF-LNPs co-encapsulated with RNA can enable stable storage of both the formulations in aqueous solution and lyophilized for at least 52 weeks at room and tropical temperatures without the need for ultracold or cold chains. Overall, PF-LNPs are a promising delivery platform amenable to large-scale manufacturing and can provide a solution to the problems of clinical translation and commercialization of nucleic acids such as RNA vaccines and biopharmaceuticals by providing a robust thermostable formulation for targeted and efficient intracellular RNA delivery.

[0300] material and method material 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), (1,2-Dioleoyl-3-dimethylammonium-propane) (DODAP), DLin-MC3-DMA, 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000), 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) lipids, cholesterol, iso-phthaloyl chloride, 6-aminofluorescein, Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin and Dulbecco's phosphate buffered saline (D-PBS) were purchased from Sigma-Aldrich (Dorset, UK). Dimethylsulfoxide (DMSO), N,N-dimethylformamide (DMF), triethylamine, sodium chloride, 4-dimethylaminopyridine (DMAP), Hoechst 33342, LysoTracker Red DND-99, Alamar Blue Assay Kit, Pierce™ LDH Cytotoxicity Assay Kit and Quant-iT RiboGreen™ Assay Kit were purchased from Fisher Scientific (Loughborough, UK). Absolute ethanol, acetone, d6-DMSO, hydrochloric acid, potassium carbonate, sodium hydroxide, methanol, diethyl ether and chloroform were obtained from VWR (Lutterworth, UK). L-lysine methyl ester dihydrochloride, L-phenylalanine methyl ester hydrochloride and N,N'-dicyclohexylcarbodiimide (DCC) were purchased from Alfa Aesar (Heysham, UK). Defibrillated sheep red blood cells (RBCs) were purchased from TCS Biosciences Ltd (Buckingham, UK). The ONE-Glo™ Luciferase Assay Kit was purchased from Promega (Southampton, UK). The polymers poly(L-lysine isophthalamide) (PLP) and PP75 were prepared according to established protocols. 4Both saRNA encoding firefly luciferase (fLuc-saRNA) and influenza virus hemagglutinin (HA-saRNA) were kindly provided by the group of Professor Robin Shattock in the Department of Infectious Diseases at St. Mary's Hospital and Imperial College London.

[0301] Lipid nanoparticle (LNP) synthesis The lipid membrane was prepared as described by Guo et al. (2015) 18 The lipids were prepared according to the method used by. Specifically, lipids at a specific concentration were dissolved in chloroform (25% (v / v) methanol). The solvent was removed by rotary evaporation for 3 h. This resulted in the formation of a thin lipid film on the inside of a round-bottom flask. The film was hydrated in a water bath at 30 °C for 1 h.

[0302] Particles were synthesized by extrusion using a mini extruder (Avanti Polar Lipids Inc., USA). The lipid solution, with or without saRNA (or co-encapsulation with other small molecules), was passed 31 times through a 0.2 μm polycarbonate membrane to form stable particles. Total lipid concentration in the formulation: ·For PF-LNP: DOTAP: 1.2mg / mL, DOPE: 1.2mg / mL, cholesterol: 1.6mg / mL; ·For PEGylated PF-LNPs: DOTAP: 11.1mg / mL, DOPE: 18.6mg / mL, cholesterol: 2.76mg / mL, DMG-PEG2000: 1.88mg / mL; ·For MC3 PF-LNP: DLin-MC3-DMA: 16.1mg / mL, DSPC: 3.67mg / mL, cholesterol: 7.44mg / mL, DMG-PEG2000: 1.88mg / mL; For DODAP PF-LNP: DODAP: 11.1mg / mL, DOPE: 18.6mg / mL, Cholesterol: 2.76mg / mL, DMG-PEG2000: 1.88mg / mL.

[0303] Formation of polymer-functionalized lipid nanoparticles (PF-LNPs) To determine the polymer coating efficiency, FITC-PP75 was used to coat particles at known concentrations: 10 mg mL using D-PBS, pH 7.4. -1 A stock solution was made and diluted to the desired concentration. This was mixed with the particle solution and allowed to adsorb overnight. Excess PP75 was removed using a dialysis device (Float-A-Lyzer®, MWCO 300 kDa, Spectrumlabs, USA). Fluorescence was measured using a spectrofluorometer (GloMax®-Multi Detection System, Promega, USA) with an excitation wavelength of 490 nm and an emission wavelength of 510-570 nm. A calibration curve was plotted using known concentrations of FITC-PP75 at pH 7.4 to correlate the fluorescence readings with concentration.

[0304] Characterization of PF-LNPs Dynamic Light Scattering (DLS) Dynamic light scattering (DLS) (Zetasizer Nano S, Malvern, UK) was used to investigate the change in hydrodynamic size of PF-LNPs. To prepare samples for DLS, PF-LNP solutions were diluted with D-PBS at pH 7.4 and equilibrated for 5 min to obtain an appropriate count rate. Samples were measured at 25°C with 13 replicates in a 10 mm diameter cell at an angle of 137°.

[0305] Zeta potential The zeta potential of PF-LNP was measured using a PALS Zeta Potential Analyzer (Brookhaven Instruments Corp., UK). To prepare samples, the PF-LNP solution was diluted with D-PBS at pH 7.4 and equilibrated for 5 min to obtain an appropriate count rate. Samples were measured at 659 nm at a fixed scattering angle of 90° with 6 replicates (20 cycles per run) at 20°C.

[0306] Cells and cultures Culture HeLa cells (human cervical cancer cells), HEK-293 cells (human embryonic kidney cells) and MRC-5 cells (lung tissue-derived fibroblasts) in complete Dulbecco's modified Eagle's medium (cDMEM) (unless otherwise specified, 10% (v / v) FBS and 100 U mL -1 For HEK-293 cells, 5 mg / mL L-glutamine was also added to the culture medium. Cells were trypsinized using trypsin-EDTA and maintained in a humidified incubator at 37° C. with 5% CO2.

[0307] Quant-iT RiboGreen™ Assay The RiboGreen™ assay was used to measure the encapsulation efficiency of saRNA. The PF-LNP solution encapsulating saRNA was diluted to 50 ng mL with dilution buffer in a 96-well plate. -1 100 μL of RiboGreen dye (Invitrogen, USA) (diluted 1:1000) was added to each well and incubated for 5 min protected from light before measuring the fluorescence intensity using a spectrofluorometer (GloMax®-Multi Detection System, Promega, USA). Samples were excited at 480 nm and emission was measured at 520 nm. A calibration curve was determined at pH 7.4 to correlate the fluorescence readings with concentration.

[0308] In vitro transfection Cell transfection studies were performed in HEK-293 and MRC5 cells. 50,000 cells per well were plated in a clear 96-well plate 48 hours prior to transfection. 100 μL of PF-LNP formulation containing 100 ng of saRNA encoding firefly luciferase (fLuc) was added to each well containing 50 μL of transfection medium (DMEM with 5 mg / mL L-glutamine). The cells were incubated for 4 hours to allow transfection to take place. The medium was then replaced with 100 μL of fresh complete DMEM and allowed to incubate for 24 hours. After 24 hours, 50 μL of medium was removed and replaced with 50 μL of ONE-Glo™ D-luciferin substrate and mixed well. 100 μL of total medium was placed in a white 96-well plate and analyzed using a spectrofluorometer (GloMax®-Multi Detection System, Promega, USA). The background from the medium control was subtracted.

[0309] Alamar Blue Assay The cytotoxicity of PF-LNPs with and without saRNA was evaluated by Alamar Blue assay. Various cell lines were seeded at a density of 100 cells per well in 96-well plates (Corning, USA) containing 100 μL of complete DMEM per well and cultured overnight. Spent medium was replaced with 100 μL of PF-LNPs solution with and without saRNA in serum-free DMEM (sterilized with 0.22 μmm filter). After incubation for a certain time interval, the medium was removed and the cells were washed three times with D-PBS. The cells were then incubated with supplemented complete DMEM containing 10% (v / v) Alamar Blue for 4 h. The fluorescence of each well was measured by a spectrofluorometer (GloMax®-Multi Detection System, Promega, USA) at an emission wavelength of 580-640 nm and an excitation wavelength of 525 nm. The fluorescence readings were used to evaluate the cytotoxicity. The concentration causing 50% inhibition, IC50, was calculated from the concentration-dependent cell viability curves.

[0310] Lactate dehydrogenase (LDH) assay The effect of PF-LNP on cell membrane integrity was determined by LDH assay. Various cell lines were seeded in 96-well plates (Corning, USA) containing complete DMEM (100 μL per well) at a density of 100 cells per well and cultured for 24 hours. Spent medium was replaced with 100 μL of serum-free DMEM containing PF-LNP with and without saRNA in serum-free DMEM (sterilized with 0.22 μm filter). After 24 hours of incubation, the released LDH in the supernatant was quantified by LDH assay. Briefly, 50 μL of the supernatant in each well was transferred to a new plate and mixed with the LDH reaction mixture from the kit. The plate was incubated for 30 minutes and the reaction was stopped using stop solution. The absorbance was measured at 490 nm and 680 nm (for reference) using a spectrofluorometer (GloMax®-Multi Detection System, Promega, USA).

[0311] Hemolysis assay The endosomolytic behavior of PF-LNP was determined by measuring the membrane disruption behavior using a hemolysis assay. Samples to be tested were prepared in D-PBS at pH 7.4 and pH 6.5. Defibrillated sheep red blood cells (RBCs) were washed three times with D-PBS to obtain a pellet of RBCs. RBCs were mixed into the samples, and approximately 2×10 were collected across all samples. 8 pieces RBC mL -1 The concentration of 0.1% was ensured, which was determined by a calibration curve. The samples were incubated in a water bath at 37°C for 1 hour with gentle agitation. The samples were then centrifuged at 3000 rpm for 3 minutes and the absorbance of the supernatant from each sample was measured using a UV-Vis spectrophotometer (GENESYS™ 10S UV-Vis, Thermo Scientific, USA) at 541 nm to determine the relative hemolysis rate.

[0312] Confocal microscopy Endocytosis Mechanism Test HEK-293 cells were plated on collagen-coated glass-bottom dishes (MatTek) at 1 × 10 cells per dish. 5 Cells were seeded at 1000 rpm and cultured for 24 hours in a 5% CO2, 37°C incubator. Pathway inhibitors in DMEM were added to each dish for 1 hour, followed by the addition of PF-LNP samples containing inhibitors. Cells were incubated for 1 hour, then samples were removed and cells were washed 3 times. Cells were then detached using trypsin-EDTA and neutralized using DMEM containing inhibitors. Cells were centrifuged at 1000 rpm for 5 minutes and the supernatant was discarded. Fresh DMEM containing specific inhibitors was added and cells were imaged using confocal microscopy.

[0313] Animal testing In vivo protein expression Six to eight week old female BALB / c mice (Charles River, UK) were injected into both hind quadriceps with 50 μL of PF-LNP formulation encapsulating fLuc-saRNA. Peak luciferase expression was then measured as previously determined for the VEEV replicon. 20 , Luciferase expression was imaged on day 7.

[0314] immunogenicity Female BALB / c mice (Charles River, UK), 6-8 weeks old, were placed in groups of n=5. Group sizes were calculated to detect a difference of 200ng / mL with a standard deviation of 40ng / mL, a statistical power of 0.9 and α=0.05. Mice were injected into one hind quadriceps with 5μg of influenza hemagglutinin (HA)-encoding saRNA in 50μL of PF-LNP formulation and boosted 4 weeks later with the same formulation. Tail bleeds were taken before each injection and 2 weeks after the booster injection. Blood was collected and centrifuged at 10,000 rpm for 5 min. Serum was harvested and stored at -20°C. Influenza challenge was introduced at week 7, at which point weight loss and survival were monitored.

[0315] HA IgG specific ELISA Previously described protocols 21A semi-quantitative immunoglobulin IgG ELISA was performed using. Briefly, recombinant HA at 1 μg / mL in PBS was coated onto ELISA plates. Standards were prepared by coating ELISA plate wells with lambda (1:1000) light chain and anti-mouse kappa (1:1000) (Southern Biotech, UK) in PBS. Plates were blocked using 1% BSA / 0.05% Tween-20 in PBS. After a washing step, diluted samples and purified IgG (Southern Biotech, UK) were added to the plate, starting at 1000 ng / mL and titrating the plate in a 5-fold dilution series, followed by a 1-hour incubation and washing step. A 1:2000 dilution of anti-mouse HA-IgG (Southern Biotech, UK) was used for detection and plates were developed using TMB (3,3',5,5'-tetramethylbenidine). After 5 min, the reaction was stopped with stop solution (Insight Biotechnologies, UK). Absorbance was read on a spectrophotometer (VersaMax, Molecular Devices) using SoftMax Pro GxP v5 software.

[0316] Lymph node histology examination Female BALB / c mice (Charles River, UK) aged 6–8 weeks were placed in groups of n=3. Mice were injected into one hind limb quadriceps with 5 μg of EGFP-saRNA in 50 μL of PF-LNP formulation coated with Cy5-PP75. The formulation was allowed to drain into lymph nodes for 1 h, after which they were harvested and fixed in 15% and then 30% sucrose solution. Lymph nodes were then cryo-embedded at -20°C in optimal cutting temperature (OCT) and sliced ​​at 5 μm using a rotary microtome (CryoStar NX70 Cryostat, UK). Samples were collected onto POLYSINE™ microscope glass slides (Thermo Fisher Scientific, UK) and left to air dry for 1 h. Sample slides were then rinsed in tap water, stained with Oil Red O filtered solution for 20 min, and washed with distilled water. They were then counterstained in Gill 1 hematoxylin for 1-2 min followed by washing with tap water. The specimen slides were then differentiated for a few seconds in 1% acid alcohol and washed in running water to turn blue. Finally, the specimens were rinsed in distilled water and a coverslip in aqueous apical media was applied as mounting medium to the top of the slides. The specimens were allowed to dry overnight and the lymph node samples were imaged using an inverted widefield microscope (Zeiss Axio Observer, UK).

[0317] Freeze drying saRNA-encapsulated PF-LNP formulations with trehalose coexisting both inside and outside the PF-LNP were synthesized according to the protocol outlined above. The formulations were then frozen to -80°C and lyophilized overnight. The dehydrated samples were rehydrated using PBS and mixed using a vortex mixer (Velp F202A0175 Wizard Vortex Mixer, UK).

[0318] statistical analysis All data points were repeated in triplicate (n=3). Results are presented as mean values ​​with standard deviations encompassing at least 95% confidence intervals. Student's t-test was performed to assess statistical significance; P<0.05 was considered statistically significant.

[0319] References 1.Fleeton, M. N. et al. Self-Replicative RNA Vaccines Elicit Protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus. J. Infect. Dis. 183, 1395-1398 (2001). 2.Lundstrom, K. Self-replicating RNA viruses for RNA therapeutics. Molecules (2018) doi:10.3390 / molecules23123310. 3.Chen, R., Khormaee, S., Eccleston, M. E. & Slater, N. K. H. The role of hydrophobic amino acid grafts in the enhancement of membrane-disruptive activity of pH-responsive pseudo-peptides. Biomaterials 30, 1954-1961 (2009). 4.Chen, R., Eccleston, M. E., Yue, Z. & Slater, N. K. H. Synthesis and pH-responsive properties of pseudo-peptides containing hydrophobic amino acid grafts. J. Mater. Chem. (2009) doi:10.1039 / b902822f. 5.Eccleston, M. E., Slater, N. K. H. & Tighe, B. J. Synthetic routes to responsive polymers; co-polycondensation of tri-functional amino acids with diacylchlorides. React. Funct. Polym. 42, 147-161 (1999). 6.Eccleston, M. E., Kuiper, M., Gilchrist, F. M. & Slater, N. K. H. pH-responsive pseudo-peptides for cell membrane disruption. J. Control. Release 69, 297-307 (2000). 7.Chen, R., Yue, Z., Eccleston, M. E., Williams, S. & Slater, N. K. H. Modulation of cell membrane disruption by pH-responsive pseudo-peptides through grafting with hydrophilic side chains. J. Control. Release (2005) doi:10.1016 / j.jconrel.2005.07.011. 8.Ho, V. H. B., Slater, N. K. H. & Chen, R. PH-responsive endosomolytic pseudo-peptides for drug delivery to multicellular spheroids tumour models. Biomaterials 32, 2953-2958 (2011). 9.Chen, S. & Chen, R. A Virus-Mimicking, Endosomolytic Liposomal System for Efficient, pH-Triggered Intracellular Drug Delivery. ACS Appl. Mater. Interfaces 8, 22457-22467 (2016). 10.Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem. J. (2004) doi:10.1042 / BJ20031253. 11.Nakamura, T. et al. The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution. Mol. Pharm. 17, 944-953 (2020). 12.Tribet, C. & Vial, F. Flexible macromolecules attached to lipid bilayers: Impact on fluidity, curvature, permeability and stability of the membranes. Soft Matter (2007) doi:10.1039 / b708431p. 13.Gutierrez De Rubalcava, C. et al. Interactions between liposomes and hydroxypropylmethylcellulose. Int. J. Pharm. (2000) doi:10.1016 / S0378-5173(00)00433-6. 14.Liu, D. Z., Chen, W. Y., Tasi, L. M. & Yang, S. P. Microcalorimetric and shear studies on the effects of cholesterol on the physical stability of lipid vesicles. Colloids Surfaces A Physicochem. Eng. Asp. 172, 57-67 (2000). 15.Wu, G. & Lee, K. Y. C. Effects of poloxamer 188 on phospholipid monolayer morphology: An atomic force microscopy study. Langmuir (2009) doi:10.1021 / la802908x. 16.Guan, S. & Rosenecker, J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 24, 133-143 (2017). 17.Geall, A. J. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. 109, 14604-14609 (2012). 18.Guo, F., Yu, M., Wang, J., Tan, F. & Li, N. Smart IR780 Theranostic Nanocarrier for Tumor-Specific Therapy: Hyperthermia-Mediated Bubble-Generating and Folate-Targeted Liposomes. ACS Appl. Mater. Interfaces 7, 20556-20567 (2015). 19.Blakney, A. K., McKay, P. F. & Shattock, R. J. Structural Components for Amplification of Positive and Negative Strand VEEV Splitzicons. Front. Mol. Biosci. (2018) doi:10.3389 / fmolb.2018.00071. 20.Vogel, A. B. et al. Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Mol. Ther. 26, 446-455 (2018). 21.Badamchi-Zadeh, A. et al. Intramuscular immunisation with chlamydial proteins induces chlamydia trachomatis specific ocular antibodies. PLoS One (2015) doi:10.1371 / journal.pone.0141209.

Claims

1. A submicron particle comprising a first payload molecule, a lipid structure, and a plurality of amphiphilic polymer chains surrounding the lipid structure, wherein the first payload molecule is a polymer, optionally a nucleic acid, and the hydrophilicity of the amphiphilic polymer chains changes in response to an external stimulus.

2. 2. The submicron particle of claim 1, wherein the first payload molecule is encapsulated within the lipid structure, and alternatively or additionally, is covalently conjugated and / or physically attached to the outer surface of the lipid structure.

3. 3. The submicron particle of claim 1 or 2, wherein the first payload molecule is a nucleic acid, a peptide, an affimer, a protein, an antibody or fragment thereof, a glycoprotein, a lipopolysaccharide, a carbohydrate, a lipid, or a macrocycle.

4. The submicron particle of any one of claims 1 to 3, wherein the first payload molecule is a nucleic acid, the nucleic acid being DNA, RNA or a DNA / RNA hybrid sequence.

5. 5. The submicron particle of claim 4, wherein the RNA is a self-amplifying RNA (saRNA) or messenger RNA (mRNA).

6. The submicron particle according to any one of claims 1 to 5, wherein the lipid structure is a lipid nanoparticle or a liposome, preferably a lipid nanoparticle.

7. The submicron particle of any one of claims 1 to 6, wherein the lipid structure comprises a plurality of lipids.

8. 8. The submicron particle of claim 7, wherein at least one of the plurality of lipids comprises a cationic lipid or an ionizable lipid.

9. The cationic lipid or ionizable lipid is (i) is a polycationic lipid or is a pH-sensitive lipid; (ii) contains a positively charged or ionizable nitrogen atom; and / or (iii) exhibits a positive charge in acidic solution; 9. The submicron particle of claim 8.

10. 10. The submicron particle of claim 8 or 9, wherein the cationic or ionizable lipid is dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA), ethylphosphatidylcholine (ethyl PC), didodecyldimethylammonium bromide (DDAB), 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-cholesterol), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), DLin-MC3-DMA, 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), or heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102).

11. The plurality of lipids comprises one or more helper lipids, and optionally (i) the helper lipid is zwitterionic, preferably a phosphatidylcholine selected from DOPC, DSPC, DPPC, DDPC, DLPC, DMPC, POPC, DEPC, and L-α-phosphatidylcholine; or a phosphatidylethanolamine selected from DOPE, DMPE, DPPE, and DSPE; or (ii) the helper lipid is non-zwitterionic, preferably a phosphatidylglycerol selected from DOPG, DMPG, DPPG, DSPG, and POPG, a phosphatidylserine (including DOPS) or a phosphatidic acid selected from DMPA, DPPA, and DSPA; The submicron particle according to any one of claims 7 to 10.

12. A submicron particle according to any one of claims 7 to 11, which does not contain or comprise a zwitterionic lipid.

13. 12. The submicron particle of any one of claims 7 to 11, wherein at least one of the plurality of lipids comprises a zwitterionic lipid.

14. 14. The submicron particle of claim 13, wherein the zwitterionic lipid comprises a positively charged nitrogen atom and / or a negatively charged oxygen atom.

15. 15. A submicron particle according to any one of claims 8 to 14, wherein the weight ratio of said cationic or ionisable lipid to said helper lipid is between 20:1 and 1:20, between 10:1 and 1:10, between 5:1 and 1:5, between 4:1 and 1:4, between 3:1 and 1:3, between 2:1 and 1:2, between 1.5:1 and 1:1.5 or between 1.8:1 and 1:1.8, preferably about 1:

1.

16. 15. The submicron particle of any one of claims 7 to 14, wherein the plurality of lipids comprises at least 5%, at least 10%, at least 20%, at least 30% or at least 40% by weight of a sterol.

17. The sterol is 1~24 17. A submicron particle according to claim 16 which is or comprises an alkyl phytosterol, stigmasterol or stigmastanol, preferably cholesterol.

18. 18. The submicron particle of any one of claims 7 to 17, wherein at least one of the plurality of lipids comprises a PEGylated lipid, and optionally the PEGylated lipid constitutes between 0.1-50%, between 0.5-40%, between 1-30%, between 2-20%, between 3-10%, between 4-8% or between 5-7% by weight of the plurality of lipids.

19. 19. A submicron particle according to any one of claims 1 to 18 having an N / P ratio of between 1:100 and 100:1, between 1:50 and 80:1, between 1:10 and 60:1, between 1:5 and 50:1, between 1:3 and 40:1, between 1:2 and 30:1, between 1:1 and 25:1, between 2:1 and 20:1, between 5:1 and 15:1, or between 8:1 and 12:

1.

20. The external stimulus is (i) a chemical stimulus selected from a pH change, a specific redox potential, a specific ion, or a specific gas; (ii) a physical change selected from a change in temperature, a change in light or an electromagnetic field; or (iii) a biochemical stimulus selected from a protein, a peptide, an enzyme, glucose, or a nucleic acid, e.g., DNA. The submicron particle according to any one of claims 1 to 19,

21. 21. The submicron particle of any one of claims 1 to 20, wherein the amphiphilic polymer chains are negatively charged at a pH of at least 4 at 20°C, at least 5 at 20°C, at least 6 at 20°C, at least 6.5 at 20°C or at least 7 at 20°C.

22. The amphiphilic polymer chain comprises one or more mers of formula I: -L 1 -CH(L 3 -COR 1 )-L 2 - [I] (In the formula, L 1 is an optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, optionally substituted C 3~20 Cycloalkylene, optionally substituted C 3~20 Cycloalkenylene, optionally substituted C 3~20 Cycloalkynylene, optionally substituted C 3~12 Heterocyclylene, optionally substituted C 6~20 Arylene, optionally substituted C 5~10 Heteroarylene, CO, O, S and NR 4 comprising one or more linker elements selected from the group consisting of: L 2 and L 3 is independently absent or optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, optionally substituted C 3~20 Cycloalkylene, optionally substituted C 3~20 Cycloalkenylene, optionally substituted C 3~20 Cycloalkynylene, optionally substituted C 3~12 Heterocyclylene, optionally substituted C 6~20 Arylene, optionally substituted C 5~10 Heteroarylene, CO, O, S and NR 4 comprising one or more linker elements selected from the group consisting of: Each R 1 is independent, NR 6 R 7 , OR 10 or OH; R 4 is H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 alkynyl; R 6 and R 7 Each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 alkynyl; R 10 is an optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 alkynyl) 22. The submicron particle of any one of claims 1 to 21, comprising:

23. In at least one of the mers of formula I, R 1 23. The submicron particle of claim 22, wherein is OH.

24. The amphiphilic polymer chain comprises one or more mers of formula II: -L 4 - [II] (In the formula, L 4 is an optionally substituted C 1~30 Alkylene, optionally substituted C 2~30 Alkenylene, optionally substituted C 2~30 Alkynylene, optionally substituted C 3~20 Cycloalkylene, optionally substituted C 3~20 Cycloalkenylene, optionally substituted C 3~20 Cycloalkynylene, optionally substituted C 3~12 Heterocyclylene, optionally substituted C 6~20 Arylene, optionally substituted C 5~10 Heteroarylene, CO, O, S and NR 4 (including one or more linker elements selected from the group consisting of 24. The submicron particle of claim 22 or 23, comprising:

25. The amphiphilic polymer chain comprises a plurality of polymers of formula III: 【Chemistry 1】 (In the formula, X 1 is absent or O, S or NR 5 and R 2 is H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl, optionally substituted C 2~30 Alkynyl, optionally substituted C 6~20 Aryl, optionally substituted C 3~20 Cycloalkyl, optionally substituted C 3~20 Cycloalkenyl, optionally substituted C 3~20 cycloalkynyl, optionally substituted 5- to 20-membered heteroaryl, or optionally substituted 3- to 20-membered heterocycle; R 3 and R 5 Each independently represents H, optionally substituted C 1~30 Alkyl, optionally substituted C 2~30 Alkenyl or optionally substituted C 2~30 alkynyl; n is an integer and is at least 1; m is an integer that is 0 or at least 1. A submicron particle according to any one of claims 22 to 24, which is or comprises:

26. (i) one or more -L 4 - the block exists; (ii) one or more -L 1 -CH(L 3 -COR 1 ) -L 2 - the block is present; and / or (iii) the polymer has a random or controlled sequence; 26. The submicron particle of claim 25.

27. The amphiphilic polymer chain comprises a plurality of polymers of formula IV: 【Chemistry 2】 26. The submicron particle of claim 25, which is or comprises:

28. The polymer of formula IV has formula IVa: 【Chemistry 3】 27. The submicron particle of claim 26 having the following structure:

29. The R in the polymer 1 Between 1 and 99%, between 5 and 85%, between 10 and 60%, or between 15 and 40% of the groups are OH, and said R 1 Between 1 and 99% of the groups, and between 15 and 95% are NR 6 R 7 OR 10 The submicron particle according to any one of claims 22 to 28, wherein

30. The R in the polymer 1 Between 1 and 99%, between 15 and 95%, between 40 and 90%, or between 60 and 85% of the groups are NR 6 R 7 and R 6 is H, and R 7 but 【Chemistry 4】 30. The submicron particle of claim 29, wherein:

31. The R in the polymer 1 Between 1 and 99%, between 5 and 90%, between 10 and 80%, between 12.5 and 70%, or between 15 and 65% of the groups are NR 6 R 7 and R 6 is H, and R 7 - (CH 2 ) 6 CH 3 , -(CH 2 ) 9 CH 3 , -(CH 2 ) 13 CH 3 , -(CH 2 ) 17 CH 3 Or - (CH 2 ) 11 30. The submicron particle of claim 29, which is COOH.

32. 32. The submicron particle of any one of claims 1 to 31, wherein the amphiphilic polymer chains have a number average molecular weight of at least 1 kDa, at least 2 kDa, at least 5 kDa, at least 10 kDa, at least 15 kDa, at least 20 kDa, at least 22 kDa, at least 24 kDa, at least 24.5 kDa or at least 24.8 kDa, or less than 250 kDa, less than 100 kDa, less than 75 kDa, less than 50 kDa, less than 40 kDa, less than 30 kDa, less than 28 kDa, less than 26 kDa, less than 25.5 kDa or less than 25 kDa.

33. (i) n is an integer of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8; (ii) n is an integer less than 50, less than 40, less than 30, less than 25, less than 20, less than 15, less than 12, or less than 10; (iii) n is an integer between 1 and 50, between 2 and 40, between 3 and 30, between 4 and 25, between 5 and 20, between 6 and 15, between 7 and 12, or between 8 and 10; (iv) n is an integer of at least 5, at least 10, at least 15, at least 25, at least 50, at least 75, at least 90, or at least 95; n can be an integer less than 5,000, less than 1,000, less than 500, less than 250, less than 150, less than 125, less than 110, or less than 105; n can be an integer between 5 and 5,000, between 10 and 1,000, between 15 and 500, between 25 and 250, between 50 and 150, between 75 and 125, between 90 and 110, or between 95 and 105; (v) n is an integer between 10 and 1,000, between 15 and 750, between 25 and 500, between 40 and 250, between 60 and 200, between 90 and 170, between 110 and 150, or between 120 and 140; (vi) n is an integer of at least 100, at least 250, at least 500, at least 750, at least 1,000, at least 1,250, or at least 1,500; (vii) m is an integer of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, or at least 45; (viii) m is an integer less than 1,000, less than 500, less than 250, less than 150, less than 100, less than 80, less than 70, less than 60, or less than 55; or (ix) m is an integer between 5 and 1,000, between 10 and 500, between 15 and 250, between 20 and 150, between 25 and 100, between 30 and 80, between 35 and 70, between 40 and 60, or between 45 and 55; A submicron particle according to any one of claims 25 to 32.

34. 4. The polymer having the structure: 【Chemistry 5】 Polymer L having 100 F 50 34. The submicron particle according to any one of claims 1 to 33, wherein

35. 35. A submicron particle according to any one of claims 1 to 34, comprising a second payload molecule, optionally encapsulated within the lipid structure, alternatively or additionally covalently conjugated and / or physically attached to the outer surface of the lipid structure.

36. 35. The submicron particle of claim 34, wherein the second payload molecule is an active pharmaceutical ingredient (API), or a component thereof, or a facilitator or enabler thereof, or a macromolecule or a small molecule, optionally wherein the second payload molecule has a molecular weight of less than 900 Daltons, less than 800 Daltons, less than 700 Daltons, less than 600 Daltons, less than 500 Daltons or less than 400 Daltons.

37. A submicron particle according to any one of claims 1 to 36, comprising at least one stabilising molecule.

38. 38. A submicron particle according to claim 37, wherein the or each stabilising molecule may be a carbohydrate and / or a polyol.

39. (i) the carbohydrate is a monosaccharide selected from the group consisting of glucose; galactose; fructose; mannose; and xylose, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer, or polymorphic form thereof; (ii) the carbohydrate may be a disaccharide selected from the group consisting of trehalose; sucrose; lactose; maltose; isomaltose; lactitol; lactulose; mannobiose; and isomalt, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof; (iii) the carbohydrate is a trisaccharide selected from the group consisting of nigerotriose; maltotriose; melezitose; maltotriulose; raffinose; and kestose, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer, or polymorphic form thereof; or (iv) the carbohydrate is a polysaccharide selected from the group consisting of dextran; amylose; amylopectin; glycogen; galactogen; inulin; callose; cellulose; chitosan; and chitin, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer, or polymorphic form thereof; 39. The submicron particle of claim 38.

40. 39. The submicron particle of claim 38, wherein the carbohydrate is trehalose, or a pharma- ceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof.

41. 41. A submicron particle according to any one of claims 1 to 40, comprising at least one targeting ligand or moiety, which is or comprises at least one of a peptide, a protein, an aptamer, a carbohydrate, an oligosaccharide, folic acid or a folate, and an antibody or an antigen-binding fragment thereof, a vitamin or a derivative thereof.

42. 1. A method for producing a submicron particle, comprising combining a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains to produce said submicron particle, said first payload molecule being a macromolecule, optionally a nucleic acid, and wherein the hydrophilicity of said amphiphilic polymer chains changes in response to an external stimulus.

43. 43. The method of claim 42, comprising contacting the first payload molecule with a plurality of lipids to produce a lipid structure that encapsulates the first payload molecule or is covalently conjugated and / or physically attached to the first payload molecule on its outer surface, and then contacting the lipid structure with a plurality of amphiphilic polymer chains to produce the submicron particle.

44. 44. The method of claim 42 or 43, comprising contacting the first payload molecule, the second payload molecule and a plurality of lipids to produce a lipid structure that encapsulates the first and second payload molecules or is covalently conjugated and / or physically attached on its outer surface to the first and second payload molecules; and then contacting the lipid structure with the plurality of amphiphilic polymer chains to produce the submicron particle.

45. 45. The method of any one of claims 42 to 44, used to modify existing lipid structures, including lipid nanoparticles and liposomal systems.

46. Submicron particles obtained or obtainable by the method according to any one of claims 42 to 45.

47. A composition, preferably a pharmaceutical composition, comprising submicron particles according to any one of claims 1 to 41 or claim 46, comprising a pharma-ceutically acceptable vehicle.

48. 11. A method of preparing a pharmaceutical composition comprising contacting a plurality of submicron particles according to any one of claims 1 to 41 or claim 46 with a pharma- ceutically acceptable vehicle.

49. A submicron particle according to any one of claims 1 to 41 or claim 46, or a composition according to claim 47, for use as a medicament.

50. A vaccine composition comprising a submicron particle according to any one of claims 1 to 41 or claim 46, or a composition according to claim 47.

51. A submicron particle according to any one of claims 1 to 41 or claim 46, or a composition according to claim 47, or a vaccine according to claim 50, for use in stimulating an immune response in a subject.

Citation Information

Patent Citations

  • ph-sensitive polymer

    JP2005531649A

  • Vectors containing polymer-modified siRNA liposomes

    JP2008509205A

  • Method for producing lipid nanoparticles for drug delivery

    JP2015502345A

  • Poly(L-lysine isophthalamide) (PLP) polymers with hydrophobic pendant chains

    JP2019531330A

  • Hypercoiling polymers and their use in cellular delivery

    US20060172418A1